Canadian General Investments: Report of Voting Results

TORONTO, April 22, 2021 (GLOBE NEWSWIRE) — This report is filed under section 16.3 of National Instrument 81-106 Investment Fund Continuous Disclosure in respect of the annual general meeting of shareholders of Canadian General Investments, Limited (the “Corporation”) held on April 22, 2021 (the “Meeting”).

There were 14,782,173 common shares represented in person or by proxy at the Meeting (equal to 70.86% of the issued and outstanding common shares).

Each of the seven nominees proposed by management for election as a director of the Corporation, as listed in the management information circular dated February 26, 2021, was elected as a director of the Corporation by votes cast at the Meeting. The detailed results of the vote for the election of each director are set out below.

Name of director Votes for
appointment
to the Board of
Directors
Votes for
as a % of
votes cast
Votes
withheld
Votes withheld
as a % of
votes cast
         
James F. Billett 14,211,722 99.68 45,409 0.32
Marcia L. Brown 14,211,222 99.68 45,909 0.32
A. Michelle Lally 14,153,117 99.27 104,014 0.73
Jonathan A. Morgan 14,043,063 99.50 214,068 1.50
Vanessa L. Morgan 14,220,350 99.74 36,781 0.26
R. Neil Raymond 14,219,950 99.74 37,181 0.26
Michael A. Smedley 14,221,922 99.75 35,209 0.25

In addition, PricewaterhouseCoopers LLP was reappointed as auditor of the Corporation and the directors authorized to fix its remuneration by way of votes cast at the Meeting.

FOR FURTHER INFORMATION PLEASE CONTACT:
Canadian General Investments, Limited
Jonathan A. Morgan
President & CEO
Phone: (416) 366-2931
Fax: (416) 366-2729
e-mail: [email protected]
website: www.canadiangeneralinvestments.ca

 



Moog Inc. Announces Second Quarter Fiscal Year 2021 Earnings Webcast on April 30, 2021

Moog Inc. Announces Second Quarter Fiscal Year 2021 Earnings Webcast on April 30, 2021

EAST AURORA, N.Y.–(BUSINESS WIRE)–
Moog Inc. (NYSE: MOG.A and MOG.B) will release its second quarter fiscal 2021 earnings for the period ended April 3, 2021 on Friday, April 30, 2021. In conjunction with this release, Moog will host a conference call beginning at 10:00 a.m. ET, which will be simultaneously broadcast live over the Internet. John Scannell, Chairman and CEO, and Jennifer Walter, CFO, will host the call.

Listeners can access the conference call live or in replay mode on the Internet at http://www.moog.com/investors/communications/. Please allow 15 minutes prior to the call to visit the site to download and install any necessary audio software.

Supplemental data will be available on the website approximately 90 minutes prior to the call and will be archived for 45 days.

Moog Inc. is a worldwide designer, manufacturer, and integrator of precision control components and systems. Moog’s high-performance systems control military and commercial aircraft, satellites and space vehicles, launch vehicles, missiles, automated industrial machinery, wind energy, marine and medical equipment. Additional information about the Company can be found at www.moog.com.

Ann Marie Luhr

716-687-4225

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Other Defense Contracts Maritime Air Engineering Transport Aerospace Manufacturing Defense

MEDIA:

Logo
Logo

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Infinity Q Diversified Alpha Fund (IQDAX; IQDNX) Investors of Imminent April 27th Deadline in Securities Class Action, Encourages Investors with Losses to Contact the Firm Now

SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) — Hagens Berman urges Infinity Q Diversified Alpha Fund (NASDAQ: IQDAX; IQDNX) (the “Fund”) investors with significant losses to submit your losses now. A securities fraud class action with an April 27th lead plaintiff deadline has been filed after advisor Infinity Q Capital Management admitted to mispricing the Fund’s NAV resulting in the Fund being liquidated. Contact us to discuss your potential ability to be a lead plaintiff.

Class Period: Dec. 21, 2018 – Feb. 22, 2021
Lead Plaintiff Deadline: Apr. 27, 2021
Visit:www.hbsslaw.com/investor-fraud/IQDAX
Contact An Attorney Now:[email protected]
                                            844-916-0895

Infinity Q Diversified Alpha Fund (NASDAQ: IQDAX; IQDNX) Securities Fraud Class Action:

The complaint alleges defendants misrepresented and concealed that (1) the Fund’s Chief Investment Officer manipulated variables going into valuation of significant Fund assets, (2) as a consequence, the Fund and its advisor would not be able to correctly calculate the Fund’s net asset value (“NAV”), (3) previously reported NAVs were unreliable, and (4) because of the foregoing the fund would halt redemptions and liquidate assets.

The truth emerged on Feb. 22, 2021, when Bloomberg published an article entitled “Mutual Fund Locks Out Founder After SEC Questions Swaps Pricing” reporting that the fund’s advisor (1) cut off founder, majority owner, and CIO James Velissaris’ access to accounts and trading, and (2) had verified that Velissaris did in fact access and alter the third-party valuation models pertaining to hundreds of millions of dollars of swaps.

Most recently, on Mar. 29, 2021

Institutional Investor

reported that as of Mar. 25, 2021, Infinity Q calculated the NAV for the fund to be $1.25 billion, about $477.7 million (27%) lower than the Feb. 18, 2021 NAV calculation.

“We’re focused on investors’ losses and proving defendants intentionally inflated the fund’s NAV,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are an Infinity Q Diversified Alpha Fund investor and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Infinity Q Diversified Alpha Fund should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].


About Hagens Berman


Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895



Enterprise Bancorp, Inc. Announces First Quarter Financial Results

LOWELL, Mass., April 22, 2021 (GLOBE NEWSWIRE) — Enterprise Bancorp, Inc. (NASDAQ: EBTC), parent of Enterprise Bank, announced net income for the three months ended March 31, 2021 of $10.4 million, or $0.86 per diluted common share, compared to $4.0 million, or $0.34 per diluted common share, for the three months ended March 31, 2020.

As previously announced on April 20, 2021, the Company declared a quarterly dividend of $0.185 per common share to be paid on June 1, 2021 to shareholders of record as of May 11, 2021.

Chief Executive Officer Jack Clancy commented, “Our first quarter 2021 results compared to 2020 were largely the result of growth in net interest income and a decrease in the provision for credit losses. As of March 31, 2021, both loans and customer deposits have grown significantly compared to March 31, 2020, with loan growth derived principally from PPP loans, which has also positively impacted deposit growth. Deposit growth has additionally benefited from government stimulus checks and customers proactively building liquidity in response to the economic uncertainty caused by the pandemic. We anticipate that as the majority of outstanding PPP loans are forgiven or paid off, which we believe will occur principally during the remainder of 2021, and as customers spend down their PPP funds, that we will likely experience a reduction in assets, loans and deposits.”

Mr. Clancy further commented, “The government’s extension of the Paycheck Protection Program has continued to be a significant initiative for the Bank in 2021 and has provided much needed financial support to many of our customers. We have actively participated in round three of the PPP, which began on January 11, 2021, and through April 20, 2021 we have received approval from the SBA for 1,317 PPP loans amounting to $200.9 million with an average loan size of $153 thousand. In total, we have received approval from the SBA for 4,080 PPP loans amounting to $710.3 million and received $25.8 million in SBA fees since the program began in April 2020.”

As previously announced on April 2, 2021, the Company redeemed on March 31, 2021, $15.0 million in 6.00% fixed-to-floating rate subordinated notes that were issued in January 2015 and due on January 30, 2030. Founder and Chairman of the Board George Duncan noted, “The opportunity to prepay the subordinated notes resulted from our strong capital and allowance for credit loss positions, the $60.0 million in subordinated notes we issued last July, and the stabilizing economy. The early redemption resulted in an expense of approximately $713 thousand which will be recovered through a reduction in interest expense in approximately nine months and will result in annual pre-tax savings of approximately $900 thousand beginning in 2022.”

Mr. Duncan further commented, “We remain steadfastly committed to our long-term focus of serving our customers, building relationships, investing in our future, cultivating our digital evolution, expanding our market area, and further developing our services and products. Regarding our branch network, we opened our 26th branch in North Andover, Massachusetts in January 2021 and expect to open our 27th branch in Londonderry, New Hampshire in early 2022. We are relocating our Lawrence, Massachusetts branch this summer within the same building to the end unit to provide for a drive-up window and drive-up ATM and will also move from our temporary Lexington, Massachusetts location later this year to a prime location in the Lexington downtown area where we will have dedicated parking and a vestibule for an ATM and night-time deposit drop.”

Mr. Clancy and Mr. Duncan jointly added, “We want to thank our valued customers for their patience and understanding over the past year as we navigated through the various pandemic protocols which were all intended to keep everyone safe. We have been intensely focused on our team members’ and customers’ safety and well-being. We want to thank every team member in our Enterprise family. We could not be prouder of the dedication, care and teamwork each team member has displayed for our customers and each other. It has really energized us both and we look forward to continued growth and achievement in the years to come.”


Paycheck Protection Program (



PPP



)

Throughout this press release we have noted certain balances, ratios or other measures of the Company’s performance which exclude the impact of PPP loans, which we expect to be short-term in nature. We refer to any balance, ratio or measure that excludes PPP loans as core. The core balances, ratios and measures were derived in order to provide more meaningful comparisons to prior periods as the majority of PPP loans outstanding are expected to pay off during the next several quarters. The table on page 9 provides a reconciliation of the non-GAAP measures to the information presented under U.S. generally accepted accounting principles (“GAAP”).

The PPP was created by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and instituted by the Small Business Administration (“SBA”). The PPP allowed entities to apply for a 1.00% interest rate loan with payments generally deferred until the date the lender receives the applicable forgiveness amount from the SBA. The PPP loans may be partially or fully forgiven by the SBA if the entity meets certain conditions. The maturity term for any principal portion left unforgiven is either 2 or 5 years from the funding date, depending on when the loan was originated. All PPP loans are fully guaranteed by the SBA and are included in total loans.

As of March 31, 2021, the Company had 3,150 PPP loans outstanding with a principal balance of $496.5 million and deferred SBA fees of $12.3 million.


Results of Operations

Net income for the three months ended March 31, 2021 amounted to $10.4 million, an increase of $6.3 million, compared to the three months ended March 31, 2020. The increase in net income for the three months ended March 31, 2021 was driven primarily by an increase in net interest income and a decrease in the provision for credit losses, partially offset by an increase in non-interest expense.

Net interest income for the three months ended March 31, 2021 amounted to $34.7 million, an increase of $4.8 million, or 16%, compared to the three months ended March 31, 2020. The increase in net interest income was due largely to interest-earning asset growth, primarily in PPP loans, and lower deposit interest expense, partially offset by an increase in subordinated debt interest expense. For the three months ended March 31, 2021, net interest income included $1.1 million in PPP interest income and $4.9 million in PPP related SBA fee income.

Average loan balances (including loans held for sale) increased $468.7 million, or 18%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. Average balances, excluding PPP loans, have remained relatively unchanged compared to the three months ended March 31, 2020. Tax equivalent net interest margin (“net interest margin” or “margin”) was 3.62%, 3.49%, and 3.89% for the three months ended March 31, 2021, December 31, 2020, and March 31, 2020, respectively. The change in net interest margin for the three months ended March 31, 2021 compared to March 31, 2020, resulted primarily from lower interest rates and interest-earning asset yields declining more than the cost of funds.

Margin for the three months ended March 31, 2021 and December 31, 2020 was positively impacted by accelerated SBA fee income on PPP loan forgiveness and negatively impacted by large interest-earning deposit balances, which consists primarily of short-term, overnight balances held at the Federal Reserve Bank. PPP loan forgiveness amounted to approximately $153.0 million and $46.6 million for the three months ended March 31, 2021 and December 31, 2020, respectively, resulting in higher margin for the three months ended March 31, 2021 compared to the three months ended December 31, 2020. The quarterly average interest-earning deposit balance was $279.8 million, $303.7 million and $35.5 million for the three months ended March 31, 2021, December 31, 2020, and March 31, 2020, respectively. The increase in the March 31, 2021 and December 31, 2020 periods compared to the March 31, 2020 period resulted primarily from increases in customer deposit balances and to a lesser extent funds received from PPP loan forgiveness. Adjusted net interest margin, excluding PPP loans and average interest-earning deposit balances, was 3.68%, 3.76%, and 3.92% for the three months ended March 31, 2021, December 31, 2020, and March 31, 2020, respectively.

For the three months ended March 31, 2021, the provision for credit losses amounted to $680 thousand, compared to $6.1 million for the three months ended March 31, 2020. The provision for the quarter ended March 31, 2021 resulted from an increase in specific reserves and a change in loan mix, partially offset by a slight decrease in core loans during the period. The provision for the prior year quarter reflected increases in reserves related to the impact of COVID-19 and from an increase in impaired loan reserves.

Non-interest income for the three months ended March 31, 2021, amounted to $4.3 million, an increase of $101 thousand, or 2%, compared to the three months ended March 31, 2020. Quarter-to-date non-interest income increased in 2021 due primarily to increases in wealth management fees and gains on equity investment fair values, partially offset by a decrease in loan derivative fees. The latter two items are included in other income.

Non-interest expense for the three months ended March 31, 2021, amounted to $24.7 million, an increase of $2.0 million, or 9%, compared to the three months ended March 31, 2020. Increases in non-interest expense in the first quarter of 2021 related primarily to the Company’s strategic growth initiatives, particularly salaries and employee benefits, and to a lesser extent occupancy, technology and telecommunications expenses. The increase in non-interest expense also resulted from a loss of $713 thousand on the early redemption of $15.0 million in 6.00% fixed-to-floating rate subordinated notes issued in January 2015 and due in January 2030. The loss on the extinguishment of subordinated debt consisted of $600 thousand in prepayment penalties and $113 thousand in unamortized issuance costs.


CECL Adoption

In the first quarter of 2021, the Company adopted the Financial Accounting Standards Board’s Accounting Standards Update 2016-13, Measurement of Credit Losses on Financial Instruments, including the current expected credit losses (“CECL”) methodology for estimating the allowance for credit losses (“ACL”). The CECL methodology requires earlier recognition of credit losses using a lifetime credit loss measurement approach that also requires the consideration of reasonable and supportable forecasts in the estimate.

The adoption of CECL resulted in the Company recording a net cumulative-effect adjustment, effective January 1, 2021, that decreased retained earnings by $6.5 million, net of $2.5 million in deferred income taxes. The ACL for loans increased by $6.6 million and the ACL for unfunded commitments (included in other liabilities) increased by $2.4 million.


Credit Quality

At March 31, 2021, the ACL for loans amounted to $49.9 million, or 1.60% of total loans and 1.90% of total core loans, compared to $44.6 million, or 1.45% of total loans and 1.69% of core loans at December 31, 2020. The ACL for unfunded commitments amounted to $2.5 million.

Net charge-offs for the quarters ended March 31, 2021 and December 31, 2020 amounted to $1.8 million and $1.4 million, respectively, compared to net recoveries of $3 thousand for the quarter ended March 31, 2020. The net charge-offs for the quarter ended March 31, 2021, related primarily to an individually evaluated commercial real estate loan, which was fully reserved in late 2020. The charge-off resulted in the loan being recorded at the estimated fair value less cost to sell the underlying collateral. The Company transferred the property to other real estate owned (“OREO”) in April 2021 by accepting the deed in-lieu of foreclosure.

As of March 31, 2021, short-term payment deferrals due to the COVID-19 pandemic remained active on 31 loans, amounting to $39.9 million, or 1.52%, of total core loans, compared to 47 loans amounting to $46.7 million, or 1.78%, of total core loans, as of December 31, 2020. As of April 20, 2021, the balance of loans with a short-term payment deferral was reduced to 0.75% of total core loans.

Non-performing assets are comprised of non-accrual loans and OREO. The Company had no OREO at March 31, 2021, December 31, 2020 or March 31, 2020. As noted above, in April of 2021, the Company transferred a commercial office building with a net book value of $2.4 million to OREO. Non-performing assets to total core assets amounted to 0.94% at March 31, 2021, compared to 1.07% and 0.47% at December 31, 2020 and March 31, 2020, respectively.

Non-performing loans to total core loans amounted to 1.36% at March 31, 2021, compared to 1.45% and 0.59% at December 31, 2020 and March 31, 2020, respectively. The increase at March 31, 2021, compared to March 31, 2020, was due to credit downgrades partially offset by payoffs, credit upgrades and charge-offs since the prior period. Credit downgrades included three commercial relationships which became non-accrual in the fourth quarter of 2020 and are in industries that have been highly impacted by the pandemic. One of these relationships had a charge-off of $1.8 million during the quarter ended March 31, 2021, which largely accounted for the decrease compared to December 31, 2020. This relationship was transferred to OREO in April 2021.


Key Financial Highlights

  • Total assets amounted to $4.26 billion at March 31, 2021, compared to $4.01 billion at December 31, 2020, an increase of $243.4 million, or 6%. Total core assets have increased $202.3 million, or 6%, since December 31, 2020.
  • The increase in total assets since December 31, 2020, is related primarily to the increase in interest-earning deposits of $187.6 million. Total interest-earning deposits, which consists primarily of short-term, overnight balances held at the Federal Reserve Bank, amounted to $400.8 million at March 31, 2021 compared to $213.1 million at December 31, 2020. The increase relates primarily to increases in customer deposit balances, and to a lesser extent, funds received from the SBA for PPP loan forgiveness.
  • Total loans amounted to $3.11 billion at March 31, 2021, compared to $3.07 billion at December 31, 2020, an increase of $35.5 million, or 1%. Total core loans have decreased slightly since December 31, 2020.
  • Customer deposits amounted to $3.74 billion at March 31, 2021, compared to $3.48 billion at December 31, 2020, an increase of $264.9 million, or 8%. Management believes the deposit growth since December 31, 2020 was due in large part to customers depositing funds received from round three PPP loan advances, stimulus checks, and generally maintaining higher liquidity in response to the pandemic.
  • Investment assets under management, which are not carried as assets on the Company’s Consolidated Balance Sheets, amounted to $930.2 million at March 31, 2021, compared to $1.00 billion at December 31, 2020, a decrease of $73.6 million, or 7%. The decrease resulted primarily from the departure of a large, institutional relationship, following the client’s merger, partially offset by net new assets and increases in market values.
  • The Total Regulatory Capital and Tier 1 Capital to risk weighted asset ratios for the Company, on a consolidated basis, were 14.28% and 10.94%, respectively, at March 31, 2021, compared to 14.62% and 10.77%, respectively, at December 31, 2020, and 11.61% and 9.84%, respectively, at March 31, 2020.
  • The decrease in the Company’s Total Regulatory Capital since December 31, 2020 primarily reflects the March 31, 2021 redemption of $15.0 million in fixed-to-floating rate subordinated notes issued in January 2015 and due in January 2030. The subordinated notes were classified as Tier 2 capital for the Company and Tier 1 capital was not impacted by the redemption. Additionally, Total Regulatory Capital and Tier 1 Capital were impacted by the $6.5 million deduction from the adoption of CECL, offset by net income less dividends paid.
  • The increase in the Company’s Total Regulatory Capital to risk weighted asset ratio since March 31, 2020 reflects primarily the Company’s issuance of $60.0 million in fixed-to-floating rate subordinated notes in July 2020. The July 2020 notes were classified as Tier 2 regulatory capital for the Company and did not impact the Company’s Tier 1 capital ratios. Additionally, the Total Regulatory Capital and Tier 1 Capital ratios increased over the period from growth in net income less dividends paid, and from low core loan growth during the period. Despite the increase in Tier 1 capital, the Company’s Tier 1 capital to average assets ratio did not increase due to average asset growth from PPP loans, which are excluded from the risk weighted capital ratios.
  • During the quarter, the Bank’s Total Regulatory and Tier 1 capital ratios were impacted by the adoption of CECL and the redemption of the subordinated notes.

Enterprise Bancorp, Inc. is a Massachusetts corporation that conducts substantially all its operations through Enterprise Bank and Trust Company, commonly referred to as Enterprise Bank, and has reported 126 consecutive profitable quarters. Enterprise Bank is principally engaged in the business of attracting deposits from the general public and investing in commercial loans and investment securities. Through Enterprise Bank and its subsidiaries, the Company offers a range of commercial, residential and consumer loan products, deposit products and cash management services, electronic and digital banking options, and commercial insurance services, as well as wealth management, and trust services. The Company’s headquarters and Enterprise Bank’s main office are located at 222 Merrimack Street in Lowell, Massachusetts. The Company’s primary market area is the Greater Merrimack Valley, Nashoba Valley, and North Central regions of Massachusetts and Southern New Hampshire (Southern Hillsborough and Rockingham counties). Enterprise Bank has 26 full-service branches located in the Massachusetts communities of Acton, Andover, Billerica (2), Chelmsford (2), Dracut, Fitchburg, Lawrence, Leominster, Lexington, Lowell (2), Methuen, North Andover, Tewksbury (2), Tyngsborough and Westford and in the New Hampshire communities of Derry, Hudson, Nashua (2), Pelham, Salem and Windham. The Company is in the process of establishing a branch office in Londonderry, New Hampshire and anticipates that this location will open in early 2022.

This earnings release contains statements about future events that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by references to a future period or periods or by the use of the words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “assume,” “will,” “should,” “plan,” and other similar terms or expressions. Forward-looking statements should not be relied on because they involve known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company. These risks, uncertainties and other factors may cause the actual results, performance, and achievements of the Company to be materially different from the anticipated future results, performance or achievements expressed in, or implied by, the forward-looking statements. Factors that could cause such differences include, but are not limited to, general economic conditions, the impact of the ongoing COVID-19 pandemic, changes in interest rates, regulatory considerations, competition and market expansion opportunities, changes in non-interest expenditures or in the anticipated benefits of such expenditures, the receipt of required regulatory approvals, changes in tax laws, and current or future litigation, regulatory examinations or other legal and/or regulatory actions, including as a result of our participation in and execution of government programs related to the COVID-19 pandemic. Therefore, the Company can give no assurance that the results contemplated in the forward-looking statements will be realized. For more information about these factors, please see our reports filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”), including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q on file with the SEC, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Any forward-looking statements contained in this earnings release are made as of the date hereof, and we undertake no duty, and specifically disclaim any duty, to update or revise any such statements, whether as a result of new information, future events or otherwise, except as required by applicable law.



ENTERPRISE BANCORP, INC.

Consolidated Balance Sheets
(unaudited)

(Dollars in thousands, except per share data)   March 31,

2021
  December 31,

2020
  March 31,

2020
Assets            
Cash and cash equivalents:            
Cash and due from banks   $ 40,539     $ 40,636     $ 32,833  
Interest-earning deposits   400,777     213,146     42,024  
Total cash and cash equivalents   441,316     253,782     74,857  
Investments:            
Debt securities at fair value (amortized cost of $581,360, $551,191, and $482,699, respectively)   601,264     582,303     505,671  
Equity securities at fair value   1,197     746     588  
Total investment securities at fair value   602,461     583,049     506,259  
Federal Home Loan Bank stock   2,010     1,905     5,624  
Loans held for sale   7,545     371     476  
Loans:            
Total loans   3,109,360     3,073,860     2,683,927  
Allowance for credit losses   (49,899 )   (44,565 )   (39,764 )
Net Loans   3,059,461     3,029,295     2,644,163  
Premises and equipment, net   46,040     46,708     46,734  
Lease right-of-use asset   18,279     18,439     18,893  
Accrued interest receivable   15,958     16,079     12,977  
Deferred income taxes, net   16,239     11,290     9,045  
Bank-owned life insurance   31,499     31,363     30,929  
Prepaid income taxes   3,600     2,449     1,005  
Prepaid expenses and other assets   7,697     13,938     10,535  
Goodwill   5,656     5,656     5,656  
Total assets   $ 4,257,761     $ 4,014,324     $ 3,367,153  
Liabilities and Stockholders

Equity
           
Liabilities            
Deposits:            
Customer deposits   $ 3,741,146     $ 3,476,268     $ 2,912,850  
Brokered deposits   75,015     74,995      
Total deposits   3,816,161     3,551,263     2,912,850  
Borrowed funds   8,631     4,774     84,169  
Subordinated debt   58,889     73,744     14,876  
Lease liability   17,397     17,539     17,968  
Accrued expenses and other liabilities   26,979     30,638     31,756  
Accrued interest payable   949     1,940     897  
Total liabilities   3,929,006     3,679,898     3,062,516  
Commitments and Contingencies            
Stockholders

Equity
           
Preferred stock, $0.01 par value per share; 1,000,000 shares authorized; no shares issued            
Common stock, $0.01 par value per share; 40,000,000 shares authorized;
12,007,998 shares issued and outstanding at March 31, 2021;
11,937,795 shares issued and outstanding at December 31, 2020; and
11,897,322 shares issued and outstanding at March 31, 2020
  120     119     119  
Additional paid-in capital   97,970     97,137     94,920  
Retained earnings   216,610     214,977     193,791  
Accumulated other comprehensive income   14,055     22,193     15,807  
Total stockholders’ equity   328,755     334,426     304,637  
Total liabilities and stockholders’ equity   $ 4,257,761     $ 4,014,324     $ 3,367,153  



ENTERPRISE BANCORP, INC.

Consolidated Statements of Income
(unaudited)

    Three months ended
    March 31,
(Dollars in thousands, except per share data)   2021   2020
Interest and dividend income:        
Loans and loans held for sale   $ 33,650      $ 31,298   
Investment securities   3,394      3,484   
Other interest-earning assets   65      165   
Total interest and dividend income   37,109      34,947   
Interest expense:        
Deposits   1,323      4,405   
Borrowed funds       415   
Subordinated debt   1,042      231   
Total interest expense   2,373      5,051   
Net interest income   34,736      29,896   
Provision for credit losses   680      6,147   
Net interest income after provision for credit losses   34,056      23,749   
Non-interest income:        
Wealth management fees   1,612      1,440   
Deposit and interchange fees   1,606      1,691   
Income on bank-owned life insurance, net   136      153   
Net gains on sales of debt securities   128      100   
Net gains on sales of loans   128      147   
Other income   689      667   
Total non-interest income   4,299      4,198   
Non-interest expense:        
Salaries and employee benefits   15,721      14,819   
Occupancy and equipment expenses   2,381      2,176   
Technology and telecommunications expenses   2,554      2,188   
Advertising and public relations expenses   514      645   
Audit, legal and other professional fees   567      605   
Deposit insurance premiums   356      404   
Supplies and postage expenses   227      247   
Loss on extinguishment of subordinated debt   713      —   
Other operating expenses   1,651      1,595   
Total non-interest expense   24,684      22,679   
Income before income taxes   13,671      5,268   
Provision for income taxes   3,319      1,251   
Net income   $ 10,352      $ 4,017   
         
Basic earnings per common share   $ 0.87      $ 0.34   
Diluted earnings per common share   $ 0.86      $ 0.34   
         
Basic weighted average common shares outstanding   11,959,469      11,841,392   
Diluted weighted average common shares outstanding   11,994,437      11,877,031   



ENTERPRISE BANCORP, INC.

Selected Consolidated Financial Data and Ratios
(unaudited)

    At or for the

three months ended
  At or for the

year ended
  At or for the

three months ended
(Dollars in thousands, except per share data)   March 31,

2021
  December 31,

2020
  March 31,

2020
BALANCE SHEET DATA            
Total assets   $ 4,257,761     $ 4,014,324     $ 3,367,153   
Loans serviced for others   80,176       78,991     97,195   
Investment assets under management   930,226       1,003,841     793,185   
Total assets under management   $ 5,268,163     $ 5,097,156     $ 4,257,533   
             
INCOME STATEMENT RATIOS (annualized)            
Return on average total assets   1.03 %   0.82  %   0.49  %
Return on average stockholders’ equity   12.78 %   9.95  %   5.34  %
Net interest margin (tax equivalent)(1)   3.62 %   3.59  %   3.89  %
             
STOCKHOLDERS EQUITY RATIOS            
Book value per common share   $ 27.38     $ 28.01     $ 25.61  
Dividends paid per common share   $ 0.185     $ 0.700     $ 0.175  
             
CAPITAL RATIOS            
Total capital to risk weighted assets   14.28 %   14.62  %   11.61  %
Tier 1 capital to risk weighted assets   10.94 %   10.77  %   9.84  %
Tier 1 capital to average assets   7.62 %   7.52  %   8.69  %
Common equity tier 1 capital to risk weighted assets   10.94 %   10.77  %   9.84  %
             
CREDIT QUALITY DATA            
Non-performing assets   $ 35,630     $ 38,050     $ 15,801  
Non-performing assets to total assets   0.84 %   0.95  %   0.47  %
Non-performing assets to total core assets   0.94 %   1.07  %   0.47  %
Non-performing loans to total loans   1.15 %   1.24  %   0.59  %
Non-performing loans to total core loans   1.36 %   1.45  %   0.59  %
Allowance for credit losses to total loans   1.60 %   1.45  %   1.48  %
Allowance for credit losses to total core loans   1.90 %   1.69  %   1.48  %

(1)   Tax equivalent net interest margin is net interest income adjusted for the tax equivalent effect associated with tax exempt loan and investment income, expressed as a percentage of average interest-earning assets.

Enterprise Bank’s capital ratios as of the periods indicated:

    March 31,

2021

(2)
  December 31,

2020

(2)
  March 31, 2020
Total capital to risk weighted assets   14.27  %   14.55  %   11.60  %
Tier 1 capital to risk weighted assets   13.01  %   13.29  %   10.35  %
Tier 1 capital to average assets   9.06  %   9.27  %   9.14  %
Common equity tier 1 capital to risk weighted assets   13.01  %   13.29  %   10.35  %

(2)   Increased capital ratios since March 31, 2020 reflect the investment of $53.0 million from the Company to the Bank resulting from the Company’s issuance on July 7, 2020 of $60.0 million in subordinated notes, net income growth less dividends paid, and low core loan growth during the period. The decreased capital ratios since December 31, 2020 reflect the adoption of CECL and a dividend from the Bank to the Company to fund the redemption of the 2015 subordinated notes. Despite the increase in Tier 1 capital, the Bank’s Tier 1 capital to average assets ratio did not increase due to average asset growth from PPP loans, which are excluded from the risk weighted capital ratios.

ENTERPRISE BANCORP, INC.

Selected Consolidated Financial Data and Ratios (continued)
(unaudited)


NON-GAAP MEASURES

The accompanying unaudited consolidated interim financial statements have been prepared in accordance with GAAP. However, certain financial measures and ratios we present, including PPP-adjusted metrics are supplemental measures that are not required by, or are not presented in accordance with, GAAP. These non-GAAP measures are intended to provide the reader with additional supplemental perspectives on operating results, performance trends, and financial condition. Non-GAAP financial measures are not a substitute for GAAP measures; they should be read and used in conjunction with the Company’s GAAP financial information. In addition, the non-GAAP financial measures we present may differ from non-GAAP financial measures used by our peers or other companies.

Certain non-GAAP measures provided in this press release exclude the outstanding balance of PPP loans that the
Company began originating in April 2020, and which are expected to be short-term in nature. We refer to any
balance, ratio or measure that excludes PPP loans as “core.” The Company normalized for this activity by excluding
PPP loans from the calculations below in order to provide a more informative analysis of results.

The following table summarizes the reconciliation of GAAP items to non-GAAP items related to the impact of PPP loans on total loans and assets:

(Dollars in thousands)   March 31,

2021
  December 31,

2020
TOTAL CORE LOANS        
Total loans (GAAP)   $ 3,109,360     $ 3,073,860  
Adjustment: PPP loans   (496,457 )   (453,084 )
Adjustment: Deferred PPP fees   12,282     10,014  
Total core loans (non-GAAP)   $ 2,625,185     $ 2,630,790  
         
TOTAL CORE ASSETS        
Total assets (GAAP)   $ 4,257,761     $ 4,014,324  
Adjustment: PPP loans   (496,457 )   (453,084 )
Adjustment: Deferred PPP fees   12,282     10,014  
Total core assets (non-GAAP)   $ 3,773,586     $ 3,571,254  

 

ENTERPRISE BANCORP, INC.

Selected Consolidated Financial Data and Ratios (continued)
(unaudited)

Additional non-GAAP measures provided in this press release exclude the impact of PPP loans and interest-earning deposits, which have abnormally impacted margin over the past several quarters. Customer deposit growth has benefited from government stimulus checks and customers proactively building liquidity in response to the economic uncertainty caused by the pandemic. This deposit inflow has in turn increased our liquidity held as short-term interest-earning deposits. We refer to any balance, ratio or measure that excludes the impact of PPP loans and interest-earning deposits as “adjusted.” The Company has normalized for this activity in order to provide a more meaningful comparison to prior periods.

The following table summarizes the reconciliation of GAAP items to non-GAAP items related to the impact of PPP loans and interest-earning deposits on margin:

    Three months ended   Three months ended   Three months ended
(Dollars in thousands)   March 31,

2021
  December 31,

2020
  March 31,

2020
ADJUSTED INTEREST-EARNING ASSETS            
Total average interest-earning assets (GAAP)   $ 3,924,153     $ 3,940,679     $ 3,127,401  
Adjustment: Average PPP loans, net     (452,813)       (481,012)        
Adjustment: Average interest-earning deposits     (279,796)       (303,745)       (35,538)  
Total adjusted average interest-earning assets (non-GAAP)   $ 3,191,544     $ 3,155,922     $ 3,091,863  
                         
ADJUSTED INTEREST INCOME                        
Interest income (tax equivalent) (GAAP)   $ 37,454     $ 37,314     $ 35,307  
Adjustment: PPP income     (6,013)       (4,685)        
Adjustment: Interest on interest-earning deposits     (68)       (71)       (93)  
Adjusted interest income (tax equivalent) (non-GAAP)   $ 31,373     $ 32,558     $ 35,214  
                     
ADJUSTED NET INTEREST MARGIN                    
Net interest margin (tax equivalent) (GAAP)   3.62  %     3.49 %     3.89 %
Adjustment: PPP effect(1)   (0.23) %     (0.05) %     %
Adjustment: Interest-earning deposits effect(2)   0.29  %     0.32 %     0.03 %
Adjusted net interest margin (tax equivalent) (non-GAAP)   3.68  %     3.76 %     3.92 %

(1)   PPP loan adjustments include an elimination of average PPP loans, net of deferred SBA fees, as well as interest income on PPP loans and related SBA fee accretion, included in interest income.

(2)   Interest-earning deposit adjustments include an elimination of average interest-earning deposits, as well as interest income on interest-earning deposits, included in interest income.

Contact Info: Joseph R. Lussier, Executive Vice President, Chief Financial Officer and Treasurer (978) 656-5578



Skylight Health Files Preliminary Base Shelf Prospectus

TORONTO, April 22, 2021 (GLOBE NEWSWIRE) — Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, announced today it has filed a preliminary short form base shelf prospectus (with the securities regulators in the following provinces of Canada; Alberta, British Columbia, Manitoba and Ontario) (the “Prospectus”) and a corresponding shelf registration statement on Form F-10 with the U.S. Securities and Exchange Commission.

The Prospectus, when final and effective, will enable the Company to offer, issue and sell, from time to time: subordinate voting shares; restricted voting shares; limited voting shares; warrants; subscription receipts; debt securities; convertible securities; units; or any combination of such securities (collectively, the “Securities”) for up to an aggregate offering price of CA$100,000,000 (or its equivalent), in one or more transactions during the effective period of the Prospectus.

Skylight Health has filed the Prospectus and corresponding registration statement in order to provide the Company with greater financial flexibility going forward. The registration statement is not yet effective, and the securities may not be sold, nor may offers to buy, be accepted prior to the time the registration statement becomes effective.

“Our strategy continues to be organic growth and growth through acquisition, and we have built a robust pipeline of immediately accretive and strategic targets,” says Prad Sekar, Co-Founder and CEO. “As we move closer to our expected NASDAQ uplisting, it is more important than ever to have the financial flexibility to continue to execute on our growth and expansion strategy.” 

This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale, of the securities in any province, state, or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration of such securities under the securities laws of any such jurisdiction.

A copy of the final short form base shelf prospectus can be found on SEDAR at www.sedar.com and a copy of the registration statement can be found on EDGAR at www.sec.gov.

About Skylight Health Group

Skylight Health Group (TSXV:SHG; OTCQX:SHGFF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multi-disciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations. The Company has operations serving 16 states and continues to expand in services and locations both organically and by way of strategic acquisitions.

The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost.

For more information, please visit www.skylighthealthgroup.com or contact:

Investor Relations:

Jackie Kelly
[email protected]
416-301-2949

Currency Usage, Cautionary and Forward-Looking Statements 

All currency contained in this Press Release represent Canadian Dollars unless otherwise stated. 

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements. 

Forward-looking statements may include, without limitation, statements regarding the Company’s Prospectus and registration statement going effective and the Company’s anticipated uplist to NASDAQ. 

Although Skylight Health has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the ability of Skylight Health to execute on its business strategy, continued revenue growth in accordance with management’s expectations, operating expenses continuing in accordance with management expectations, dependence on obtaining regulatory approvals; Skylight Health being able to find, complete and effectively integrate target acquisitions; change in laws relating to health care regulation; reliance on management; requirements for additional financing; competition; hindering market growth or other factors that may not currently be known by the Company. 

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. 

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Provident Bancorp, Inc. Reports Earnings for the March 31, 2021 Quarter and Continues Payment of Quarterly Cash Dividends of $0.04 per Share

AMESBURY, Mass., April 22, 2021 (GLOBE NEWSWIRE) — Provident Bancorp, Inc. (the “Company”) (NasdaqCM: PVBC), the holding company for The Provident Bank (the “Bank”), reported net income for the three months ended March 31, 2021 of $4.3 million, or $0.24 per diluted share, compared to $1.2 million, or $0.07 per diluted share, for the three months ended March 31, 2020. The increase in net income is primarily attributable to the impact COVID-19 had on the 2020 provision for loan losses which were $3.1 million for the three months ended March 31, 2020 compared to $753,000 for the same period in 2021.

The Company also announced that its Board of Directors has declared a quarterly cash dividend of $0.04 per share, which will be paid on May 21, 2021 to stockholders of record as of May 7, 2021.

In announcing these results, Dave Mansfield, Chief Executive Officer said, “We entered this year eager to embrace the future of banking and excited to form new relationships and explore potential business opportunities. We have been particularly focused on meeting the full-service banking needs of our growing list of digital asset customers. In the first quarter we have nearly doubled our digital asset deposit portfolio. We are optimistic about putting this deposit growth to work on our robust pipeline of loans. I am very proud of our first quarter’s financial results and am encouraged by the increase in economic activity we are currently seeing and expect to continue to see as more people are vaccinated against COVID-19 and businesses are able to return to normal operations. We are excited to share our financial success and announce an increase in this quarter’s cash dividend to $0.04 per share.”

COVID–19 Response

Since the distribution of the first COVID-19 vaccination began in December, additional vaccines have been approved for use and the Company’s market area has progressed through different phases of the vaccine rollout. As larger percentages of the population become fully vaccinated, and warmer weather has begun, there has been an uptick in economic activity, particularly in those industries that had been most heavily impacted by the economic downturn caused by the COVID-19 pandemic.

In December 2020, Congress approved a bill which allocated additional funds to the Small Business Administration (“SBA”) for a second round of Paycheck Protection Program (“PPP”) loans to assist with the economic fall out caused by the COVID-19 pandemic. The SBA, in consultation with the U.S. Treasury department, announced that the PPP was to resume in January of 2021 and has since extended the program through May 31, 2021. During the first round of the PPP, which ran from March to August 2020, the Company originated $78.0 million in PPP loans. As of March 31, 2021, the Company has originated an additional $42.7 million under the second round of the PPP. The Company continues to work with customers who received PPP loans on applying for loan forgiveness, and as of March 31, 2021, of the $120.7 million in PPP loans issued, only $57.5 million remained outstanding.

The Company’s focus has been on meeting the needs of its customers through the height of the pandemic and now through the economic recovery. We continue to maintain close communication with commercial customers, especially in those industries most heavily impacted by the pandemic and continue to allow for loan deferral extensions on an as-needed and case-by-case basis. Most loans that were modified under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act have resumed repayment or have been paid off. We have not experienced any significant delinquencies related to these loans. As of Mach 31, 2021, remaining loan modifications that were made under the CARES Act totaled $35.2 million, or 2.7% of total loans, compared to $44.0 million, or 3.3% of total loans at December 31, 2020.

Financial Results

Net interest and dividend income before provision for loan losses increased by $2.8 million, or 23.5%, compared to the three months ended March 31, 2020. The growth in net interest and dividend income is primarily the result of an increase in our average interest-earning assets of $330.2 million, or 29.2%, offset by an increase in average interest-bearing liabilities of $145.7 million, or 20.4%, and a decrease in net interest margin of 19 basis points to 4.08%. The decrease in the net interest margin is the result of a combination of factors including a decreasing rate environment and an increase in mortgage warehouse loan balances, which have lower rates than our traditional commercial loans. The net interest margin benefitted from the accretion of fee income related to the forgiveness of the SBA PPP loans. The amount of income recognized from the forgiveness totaled $625,000 for the three months ended March 31, 2021. Excluding this income, net interest margin would be 3.91% for the three months ended March 31, 2021. As of March 31, 2021, there was $1.8 million in SBA PPP fee income remaining to be accreted.

Provision for loan losses of $753,000 were recognized for the three months ended March 31, 2021 compared to $3.1 million for the same period in 2020. The changes in the provision were based on management’s assessment of economic conditions, including the impact of the COVID-19 pandemic, loan portfolio growth and composition changes, historical charge-off trends, levels of problem loans and other asset quality trends.

The allowance for loan losses as a percentage of total loans was 1.43% as of March 31, 2021 compared to 1.39% as of December 31, 2020. The primary reason for the increase was a $2.4 million loan relationship that was placed on nonaccrual status and downgraded to doubtful status in the first quarter of 2021 with specific reserves of $1.5 million. This increase was partially offset by a slight decrease in the provision allocated across the portfolio due to a reduction in economic factors. In addition, there was a decrease in the provision allocated to mortgage warehouse loan balances resulting from the Bank’s seasoning experience with this line of lending. There were $244.1 million and $265.4 million in outstanding mortgage warehouse loan balances at March 31, 2021 and December 31, 2020, respectively. Loans in this segment are facility lines to non-bank mortgage origination companies for sale into secondary markets, which is typically within 15 days of the loan closure. Due to their short-term nature, these loans are assessed at a lower credit risk and do not carry the same allocation as traditional loans. Included in total loans is $57.5 million in PPP loans originated as part of the CARES Act that we believe have no credit risk due to a government guarantee, therefore we have not provided for losses for these loans. Excluding PPP loans, the allowance for loan losses as a percentage of total loans was 1.50% as of March 31, 2021 compared to 1.43% at December 31, 2020. The allowance for loan losses as a percentage of non-performing loans was 255.29% as of March 31, 2021 compared to 341.72% as of December 31, 2020. Non-performing loans were $7.5 million, or 0.48% of total assets as of March 31, 2021, compared to $5.4 million, or 0.36% of total assets, as of December 31, 2020. As of March 31, 2021, non-performing loans consist primarily of three commercial relationships totaling $5.9 million. These loan relationships were evaluated for impairment and specific reserves of $3.3 million were allocated as of March 31, 2021.

Noninterest income increased $8,000, or 0.8%, and was $1.0 million for each of the three months ended March 31, 2021 and 2020. The increase is primarily due to an increase in bank owned life insurance income and other income partially offset by a decrease in other service charges and fees. Other income increased $51,000, or 268.4% primarily due to a one-time incentive payment on a service contract. Bank owned life insurance income increased $40,000, or 22.3%, due to the purchase of additional insurance policies in 2020. Other service charges and fees decreased $110,000, or 23.9% primarily due to higher average deposit balances, which resulted in decreased overdraft fees.

Noninterest expense increased $907,000, or 10.9%, to $9.2 million for the three months ended March 31, 2021 compared to $8.3 million for the three months ended March 31, 2020. The increase is primarily due to an increase in salaries and employee benefits expense, deposit insurance expenses, data processing fees and other expenses, partially offset by a decrease in write downs of other assets and receivables. The increase of $1.1 million, or 19.9%, for the three months ended March 31, 2021 when compared to the same period in 2020 in salary and employee benefits was primarily due to stock based compensation expense and a higher number of sales and operations positions compared to the same period in 2020. Deposit insurance expenses increased $75,000, or 241.9%, primarily due to one-time credits that were recognized in the first quarter of 2020 that resulted in a lower expense. Data processing fees increased $96,000 or 42.7%, primarily due to new contracts for deposit services. These increases were offset by a decrease in write downs of other assets and receivables of $500,000. In the first quarter of 2020 a write-down of a notes receivable balance was completed after the Company evaluated the collectability and determined that $500,000 was uncollectible.

As of March 31, 2021, total assets have increased $46.1 million, or 3.1%, to $1.55 billion compared to $1.51 billion at December 31, 2020. The primary reasons for the increase are increases in cash and cash equivalents, debt securities available-for-sale and other assets, partially offset by a decrease in net loans. The increase in cash and cash equivalents of $49.1 million, or 58.5% is primarily due to an increase in deposits and loan payoffs. The increase in debt securities available-for-sale of $2.4 million, or 7.5%, resulted primarily from the purchase of a $5.0 million bond offset by principal pay downs on government mortgage-backed securities. Net loans decreased $6.7 million, or 0.5%, and was $1.31 billion as of March 31, 2021 and December 31, 2020. The decrease in net loans was due to a decreases in mortgage warehouse loans of $21.3 million, or 8.0%, commercial real estate loans of $3.9 million, or 0.9%, residential real estate loans of $2.9 million, or 8.8% and consumer loans of $1.4 million, or 25.4%, partially offset by increases in commercial loans of $19.4 million, or 3.4% and construction and land development loans of $4.9 million, or 16.8%. Included in commercial loans at March 31, 2021and December 31, 2020 are $57.4 million and $41.8 million in SBA PPP loans, respectively.

Total liabilities increased $47.8 million, or 3.8%, due to increased deposits. Deposits were $1.29 billion as of March 31, 2021, representing an increase of $47.8 million, or 3.9%, compared to December 31, 2020. The increase in deposits was due to an increase of $30.6 million, or 5.5%, in NOW and demand deposits, an increase of $33.0 million, or 9.3% in money market accounts, an increase of $4.1 million, or 2.7%, in savings accounts, partially offset by a decrease of $19.9 million, or 11.2%, in time deposits. NOW and demand deposits and money market deposits increased primarily due to funds from the origination of PPP loans and increased deposit balances from new and expanded relationships with digital asset customers, which totaled $53.7 million at March 31, 2021. The increase in savings accounts is primarily caused by increased consumer savings. The decrease in time deposits is primarily due to roll-off of brokered certificates of deposit. In addition, the Bank has increased focused on growing non-interest bearing deposit balances and as of March 31, 2021 non-interest bearing deposits represented 33.5% of total deposits compared to 31.0% at December 31, 2020.

As of March 31, 2021, shareholders’ equity was $234.1 million compared to $235.9 million at December 31, 2020, representing a decrease of $1.7 million, or 0.7%. The decrease was primarily due to the repurchase of common stock of $6.2 million, $532,000 from dividends paid and a decrease in other comprehensive income of $185,000, partially offset by net income of $4.3 million, stock-based compensation expense of $604,000 and employee stock ownership plan shares earned of $286,000.

About Provident Bancorp, Inc.

BankProv, legally operating as The Provident Bank, is a subsidiary of Provident Bancorp, Inc. (NASDAQ: PVBC). BankProv is a future-ready commercial bank for corporate clients, specializing in offering adaptive and technology-first banking solutions to niche markets, including cryptocurrency, renewable energy, fin-tech and search fund lending. We are committed to offering a state-of-the-art API suite for all business clients and BaaS (Bank as a Service) partners. Through our offerings, BankProv insures 100% of deposits through a combination of insurance provided by the Federal Deposit Insurance Corporation (FDIC) and the Depositors Insurance Fund (DIF). For more information about BankProv please visit our website www.bankprov.com or call 877-487-2977.

Forward-looking statements

This news release may contain certain forward-looking statements, such as statements of the Company’s or the Bank’s plans, objectives, expectations, estimates and intentions. Forward-looking statements may be identified by the use of words such as, “expects,” “subject,” “believe,” “will,” “intends,” “may,” “will be” or “would.” These statements are subject to change based on various important factors (some of which are beyond the Company’s or the Bank’s control) and actual results may differ materially. Accordingly, readers should not place undue reliance on any forward-looking statements (which reflect management’s analysis of factors only as of the date of which they are given). These factors include: general economic conditions; the effects of any pandemic; trends in interest rates; the ability of our borrowers to repay their loans; and the ability of the Company or the Bank to effectively manage its growth and results of regulatory examinations, among other factors. The foregoing list of important factors is not exclusive. Readers should carefully review the risk factors described in other documents of the Company files from time to time with the Securities and Exchange Commission, including Annual and Quarterly Reports on Forms 10-K and 10-Q, and Current Reports on Form 8-K.

Provident Bancorp, Inc.
Carol Houle, 603-334-1253
Executive Vice President/CFO
[email protected]

Provident Bancorp, Inc.
Consolidated Balance Sheet

  At   At
  March 31,   December 31,
  2021   2020
(Dollars in thousands) (unaudited)      
Assets          
Cash and due from banks $ 17,560     $ 11,830  
Short-term investments   115,313       71,989  
Cash and cash equivalents   132,873       83,819  
Debt securities available-for-sale (at fair value)   34,629       32,215  
Federal Home Loan Bank stock, at cost   895       895  
Loans, net of allowance for loan losses of $19,032 and $18,518 as of March 31, 2021 and December 31, 2020, respectively   1,308,136       1,314,810  
Bank owned life insurance   36,903       36,684  
Premises and equipment, net   14,655       14,716  
Accrued interest receivable   6,456       6,371  
Right-of-use assets   4,219       4,258  
Other assets   13,126       12,013  
Total assets $ 1,551,892     $ 1,505,781  
           
Liabilities and Shareholders’ Equity          
Deposits:          
Noninterest-bearing $ 431,028     $ 383,079  
Interest-bearing   854,196       854,349  
Total deposits   1,285,224       1,237,428  
Long-term borrowings   13,500       13,500  
Operating lease liabilities   4,463       4,488  
Other liabilities   14,563       14,509  
Total liabilities   1,317,750       1,269,925  
Shareholders’ equity:          
Preferred stock; authorized 50,000 shares: no shares issued and outstanding          
Common stock, $0.01 par value, 100,000,000 shares authorized; 18,574,127 and 19,047,544 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively   186       191  
Additional paid-in capital   133,981       139,450  
Retained earnings   108,273       104,508  
Accumulated other comprehensive income   873       1,058  
Unearned compensation – ESOP   (9,171 )     (9,351 )
Total shareholders’ equity   234,142       235,856  
Total liabilities and shareholders’ equity $ 1,551,892     $ 1,505,781  
               

Provident Bancorp, Inc.
Consolidated Income Statements

  Three Months Ended
  March 31,
  2021   2020
(Dollars in thousands, except per share data) (unaudited)
Interest and dividend income:          
Interest and fees on loans $ 15,697   $ 13,760
Interest and dividends on debt securities available-for-sale   169     258
Interest on short-term investments   23     71
Total interest and dividend income   15,889     14,089
Interest expense:          
Interest on deposits   911     1,646
Interest on borrowings   70     371
Total interest expense   981     2,017
Net interest and dividend income   14,908     12,072
Provision for loan losses   753     3,099
Net interest and dividend income after provision for loan losses   14,155     8,973
Noninterest income:          
Customer service fees on deposit accounts   379     352
Service charges and fees – other   350     460
Bank owned life insurance income   219     179
Other income   70     19
Total noninterest income   1,018     1,010
Noninterest expense:          
Salaries and employee benefits   6,477     5,402
Occupancy expense   412     441
Equipment expense   122     137
Deposit insurance   106     31
Data processing   321     225
Marketing expense   37     64
Professional fees   431     386
Directors’ compensation   254     194
Software depreciation and implementation   246     200
Write down of other assets and receivables       500
Other   807     726
Total noninterest expense   9,213     8,306
Income before income tax expense   5,960     1,677
Income tax expense   1,663     446
Net income $ 4,297   $ 1,231
Earnings per share:          
Basic $ 0.25   $ 0.07
Diluted $ 0.24   $ 0.07
Weighted Average Shares:          
Basic   17,263,759     18,115,970
Diluted   17,558,160     18,261,282
           

Provident Bancorp, Inc.
Net Interest Income Analysis
(Unaudited)

  For the Three Months Ended March 31,
  2021   2020
        Interest             Interest    
  Average   Earned/   Yield/   Average   Earned/   Yield/
  Balance   Paid   Rate   Balance   Paid   Rate
(Dollars in thousands)                              
Assets:                              
Interest-earning assets:                              
Loans $ 1,317,638     $ 15,697   4.77 %   $ 1,068,525     $ 13,760   5.15 %
Short-term investments   112,198       23   0.08 %     19,176       71   1.48 %
Debt securities available-for-sale   31,344       166   2.12 %     41,031       237   2.31 %
Federal Home Loan Bank stock   895       3   1.34 %     3,161       21   2.66 %
Total interest-earning assets   1,462,075       15,889   4.35 %     1,131,893       14,089   4.98 %
Non-interest earning assets   66,157                 57,183            
Total assets $ 1,528,232               $ 1,189,076            
Liabilities and shareholders’ equity:                              
Interest-bearing liabilities:                              
Savings accounts $ 151,375       55   0.15 %   $ 121,106       105   0.35 %
Money market accounts   375,078       477   0.51 %     255,883       705   1.10 %
NOW accounts   153,294       98   0.26 %     124,286       155   0.50 %
Certificates of deposit   166,388       281   0.68 %     133,819       681   2.04 %
Total interest-bearing deposits   846,135       911   0.43 %     635,094       1,646   1.04 %
Borrowings   13,500       70   2.07 %     78,869       371   1.88 %
Total interest-bearing liabilities   859,635       981   0.46 %     713,963       2,017   1.13 %
Noninterest-bearing liabilities:                              
Noninterest-bearing deposits   412,350                 226,440            
Other noninterest-bearing liabilities   17,987                 15,731            
Total liabilities   1,289,972                 956,134            
Total equity   238,260                 232,942            
Total liabilities and equity $ 1,528,232               $ 1,189,076            
Net interest income       $ 14,908             $ 12,072    
Interest rate spread (1)             3.89 %               3.85 %
Net interest-earning assets (2) $ 602,440               $ 417,930            
Net interest margin (3)             4.08 %               4.27 %
Average interest-earning assets to interest-bearing liabilities   170.08 %               158.54 %          
                                   

(1) Net interest rate spread represents the difference between the weighted average yield on interest-bearing assets and the weighted average rate of interest-bearing liabilities.
(2) Net interest-earning assets represent total interest-earning assets less total interest-bearing liabilities.
(3) Net interest margin represents net interest income divided by average total interest-earning assets.

Provident Bancorp, Inc.
Select Financial Highlights

  Three Months Ended
  March 31,
  2021   2020
(unaudited)      
Performance Ratios:      
Return on average assets (1) 1.12 %   0.41 %
Return on average equity (1) 7.21 %   2.11 %
Interest rate spread (1) (3) 3.89 %   3.85 %
Net interest margin (1) (4) 4.08 %   4.27 %
Non-interest expense to average assets (1) 2.41 %   2.79 %
Efficiency ratio (5) 57.85 %   63.49 %
Average interest-earning assets to average interest-bearing liabilities 170.08 %   158.54 %
Average equity to average assets 15.59 %   19.59 %
           

  At   At   At
  March 31,   December 31,   March 31,
  2021   2020   2020
Asset Quality                
Non-accrual loans:                
Real estate:                
Commercial $     $     $ 21,199  
Residential   969       1,156       732  
Construction and land development               165  
Commercial   6,469       4,198       2,754  
Consumer   17       65       84  
Mortgage warehouse                
Total non-accrual loans   7,455       5,419       24,934  
Accruing loans past due 90 days or more                
Other real estate owned                
Total non-performing assets $ 7,455     $ 5,419     $ 24,934  
Asset Quality Ratios                
Allowance for loan losses as a percent of total loans (2)   1.43 %     1.39 %     1.46 %
Allowance for loan losses as a percent of non-performing loans   255.29 %     341.72 %     66.87 %
Non-performing loans as a percent of total loans (2)   0.56 %     0.41 %     2.18 %
Non-performing loans as a percent of total assets   0.48 %     0.36 %     2.22 %
Non-performing assets as a percent of total assets (6)   0.48 %     0.36 %     2.22 %
Capital and Share Related                
Stockholders’ equity to total assets   15.1 %     15.7 %     20.7 %
Book value per share $ 12.61     $ 12.38     $ 11.95  
Market value per share $ 14.40     $ 12.00     $ 8.62  
Shares outstanding   18,574,127       19,047,544       19,476,248  
                       

(1) Annualized
(2) Loans are presented before the allowance but include deferred costs/fees.
(3) Represents the difference between the weighted average yield on average interest-earning assets and the weighted average cost of interest-bearing liabilities.
(4) Represents net interest income as a percent of average interest-earning assets.
(5) Represents noninterest expense divided by the sum of net interest income and noninterest income, excluding gains on securities available for sale, net.
(6) Non-performing assets consists of non-accrual loans plus loans accruing but 90 days overdue and OREO.



Groupon to Release First Quarter 2021 Financial Results on May 6, 2021

Groupon to Release First Quarter 2021 Financial Results on May 6, 2021

CHICAGO–(BUSINESS WIRE)–Groupon, Inc. (NASDAQ: GRPN) announced today that it intends to release first quarter 2021 financial results after the close of market trading on Thursday, May 6, 2021 and hold a conference call to discuss those results on Friday, May 7, 2021, at 10:00am ET.

A webcast of the conference call can be accessed live at investor.groupon.com. A replay of the webcast will be available through the same link following the conference call, along with other published materials.

About Groupon

Groupon (www.groupon.com) (NASDAQ: GRPN) is an experiences marketplace where consumers discover fun things to do and local businesses thrive. For our customers, this means giving them an amazing selection of experiences at great values. For our merchants, this means making it easy for them to partner with Groupon and reach millions of consumers around the world. To find out more about Groupon, please visit press.groupon.com.

Investor Relations Contact:

Jennifer Beugelmans or Megan Carrozza

[email protected]

Media Relations Contact:

Nick Halliwell

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Other Consumer Women Fashion Retail Men Other Entertainment Family Music Consumer Entertainment Restaurant/Bar Marketing Energy Other Retail Advertising Communications Other Travel General Entertainment Travel

MEDIA:

Logo
Logo

MidWestOne Financial Group, Inc. Reports Financial Results for the First Quarter of 2021


First


Quarter Summary



(




1)


  • Net income for the first quarter was a record $21.6 million, or $1.35 per diluted common share.
    • Total revenue, net of interest expense, increased to $50.4 million.
    • Credit loss benefit increased to $4.7 million.
    • Noninterest expense decreased to $27.7 million.
  • Efficiency ratio improved to 50.8%.
  • Average total interest earning assets grew 6.6% annualized.
  • Average total deposits grew 7.8% annualized.
  • Allowance for credit losses ratio declined to 1.5% given the improving economic outlook.
  • Nonperforming assets increased 1.9% and the net charge-off ratio was 4 bps.

IOWA CITY, Iowa, April 22, 2021 (GLOBE NEWSWIRE) — MidWestOne Financial Group, Inc. (Nasdaq: MOFG) (“we”, “our”, or the “Company”) today reported net income for the first quarter of 2021 of $21.6 million, or $1.35 per diluted common share, compared to net income of $16.7 million, or $1.04 per diluted common share, for the linked quarter.

Charles Funk, Chief Executive Officer of the Company, commented, “This is the highest earnings quarter in our Company’s history. We have seen our asset quality stabilize as the economy improves. Further, our credit loss estimate has declined from peak 2020 levels that stemmed from economic uncertainty driven by the COVID-19 pandemic. We also note our expenses are well-controlled, which is important given this period of soft loan demand.”

1First Quarter Summary compares to the linked quarter unless noted.
2Non-GAAP measure. See the Non-GAAP Measures section for a reconciliation to the most directly comparable GAAP measure.

     
FINANCIAL HIGHLIGHTS
  Three Months Ended
    March 31,   December 31,   March 31,
(Dollars in thousands, except per share amounts)   2021   2020   2020
Net interest income   $ 38,617       $ 39,037       $ 37,406    
Noninterest income   11,824       10,626       10,155    
Total revenue, net of interest expense   50,441       49,663       47,561    
Credit loss (benefit) expense   (4,734 )     (3,041 )     21,733    
Noninterest expense   27,700       31,915       30,001    
Income (loss) before income tax expense (benefit)   27,475       20,789       (4,173 )  
Income tax expense (benefit)   5,827       4,079       (2,198 )  
Net income (loss)   $ 21,648       $ 16,710       $ (1,975 )  
Diluted earnings (loss) per share   $ 1.35       $ 1.04       $ (0.12 )  
             
Return on average assets   1.59   %   1.22   %   (0.17 ) %
Return on average equity   17.01   %   13.15   %   (1.54 ) %
Return on average tangible equity(1)   21.52   %   17.07   %   (0.47 ) %
Efficiency ratio(1)   50.77   %   59.69   %   57.67   %
             
(1) Non-GAAP measure. See the Non-GAAP Measures section for a reconciliation to the most directly comparable GAAP measure.
 

COVID-19 UPDATE


Loan Modifications

As of March 31, 2021, the outstanding balance of loans modified as a result of the COVID-19 pandemic totaled $16.7 million, a decline of 62% from $44.1 million at December 31, 2020. Of those modified loans at March 31, 2021, $3.2 million were in their first deferral period while $13.5 million are in, or being processed for, an additional deferral.


SBA PPP Loans

On March 30, 2021, President Biden signed into law the PPP Extension Act of 2021, which provided an extension to May 31, 2021 for qualifying businesses to apply for a PPP loan and provided an additional 30 days for the SBA to process pending PPP loan applications. We expect the Company’s volume of PPP loan originations will decline after March 31, 2021 compared to the level of originations during the first quarter of 2021.

The following table presents PPP loan measures as of the dates indicated:

    Total PPP Loans Funded   Outstanding PPP Loans

(


1)
(Dollars in millions)   #   $   #   $   Unearned
income
March 31, 2021   4,304   $ 474.2     2,577   $ 248.7     $ 6.9  
                     
December 31, 2020   2,681   $ 348.5     2,410   $ 259.3     $ 5.3  
(1) Outstanding loans are presented net of unearned income.
 


Vulnerable Industries

We believe loans to certain industries are uniquely vulnerable to credit deterioration stemming from the COVID-19 pandemic. The following table presents our exposure to those industries as of the dates indicated.

  March 31, 2021     December 31, 2020  
(Dollars in millions)   Balance   % of Total
Loans
    Balance   % of Total
Loans
 
Non-essential Retail   $ 88.0     2.6   %   $ 95.0     2.7   %
Restaurants   56.1     1.7       49.9     1.4    
Hotels   114.4     3.4       117.0     3.4    
CRE-Retail   191.1     5.7       203.7     5.8    
Arts, Entertainment & Gaming   23.5     0.7       26.9     0.8    
Total Vulnerable Industries Loan Portfolio   $ 473.1     14.1   %   $ 492.5     14.1   %
                                 

INCOME STATEMENT HIGHLIGHTS


Net Interest Income

Net interest income decreased to $38.6 million in the first quarter of 2021 from $39.0 million in the fourth quarter of 2020 as higher average earning asset volumes were offset by a 3 basis point decline in the net interest margin. In addition, net PPP loan fee income added $4.4 million in the first quarter of 2021 compared to $3.1 million in the linked quarter, whereas loan purchase discount accretion was $1.1 million in the first quarter of 2021, down from $1.5 million in the linked quarter.

Average interest earning assets increased $81.1 million to $5.2 billion in the first quarter of 2021, compared to the fourth quarter of 2020, as cash on hand and cash inflows from net loan pay-downs and deposit activity was used to purchase debt securities. The mix of interest earning assets shifted further to debt securities as non-PPP loan demand continued to be soft and line utilization was low.

The Company’s tax equivalent net interest margin was 3.10% in the first quarter of 2021 compared to 3.13% in the linked quarter, as lower earning asset yields were only partially offset by a reduction in average funding costs. Total earning asset yields decreased 9 bps from the linked quarter, reflecting the aforementioned shift in earning asset mix to debt securities that generally have lower yields than our loan portfolio. The cost of interest bearing liabilities decreased 8 bps to 0.56%, primarily as a result of interest bearing deposit costs of 0.40%, which declined 7 bps from the linked quarter.

“Although our balance sheet continues to grow thanks to higher deposit balances, thus generating more net interest income, low loan demand has necessitated purchasing investment securities with these deposits. We were helped in the quarter by a slightly steeper yield curve, but this yield spread remains historically narrow,” stated Mr. Funk.


Noninterest Income

Noninterest income for the first quarter of 2021 increased $1.2 million, or 11%, from the linked quarter. The increase was due primarily to a $0.8 million increase in loan revenue and an increase of $0.3 million in investment services and trust activities revenue. The increase in loan revenue was due primarily to a $0.9 million increase in the fair value of our mortgage servicing rights partially offset by a $0.2 million decrease in loan sale gains. Investment services and trust activities revenue reflected the earnings benefit from increased equity market valuations and fees collected in the normal course of those lines of business.

The following table presents details of noninterest income for the periods indicated:

  Three Months Ended

Noninterest Income
March 31,   December 31,   March 31,
(In thousands) 2021   2020   2020
Investment services and trust activities $ 2,836     $ 2,518     $ 2,536  
Service charges and fees 1,487     1,571     1,826  
Card revenue 1,536     1,517     1,365  
Loan revenue 4,730     3,900     1,123  
Bank-owned life insurance 542     541     520  
Investment securities gains, net 27     30     42  
Other 666     549     2,743  
Total noninterest income $ 11,824     $ 10,626     $ 10,155  
                       


Noninterest Expense

Noninterest expense for the first quarter of 2021 decreased $4.2 million, or 13.2%, from the linked quarter due primarily to decreases in other, legal and professional, and compensation and employee benefits of $1.7 million, $1.3 million, and $0.7 million, respectively. The decrease in other noninterest expense was primarily due to a $0.8 million loss on the termination of our cash flow hedge that was recorded in the fourth quarter of 2020, which did not recur in the first quarter of 2021, coupled with a reduction in tax credit partnership investment amortization of $0.6 million. The decrease in legal and professional expenses was primarily due to a $0.6 million fee incurred during the fourth quarter of 2020 related to a large contract renewal, which did not recur in the first quarter of 2021, coupled with an overall decline in legal and professional fees paid for regulatory, personnel and other services. The decrease in compensation and employee benefits reflected a $0.9 million benefit from SBA PPP loan origination costs which are deferred and amortized over the life of the loan to which they relate, coupled with a decline of $0.5 million in commission and incentive expense. Partially offsetting these decreases in compensation and employee benefits were increased salary and benefit costs of $0.7 million which stemmed from normal annual increases. Expense control was the primary driver to improvement in the Company’s efficiency ratio, which decreased 8.92% to 50.77%, as compared to the linked quarter efficiency ratio of 59.69%.

The following table presents details of noninterest expense for the periods indicated:

  Three Months Ended

Noninterest Expense
March 31,   December 31,   March 31,
(In thousands) 2021   2020   2020
Compensation and employee benefits $ 16,917     $ 17,638     $ 16,617  
Occupancy expense of premises, net 2,318     2,476     2,341  
Equipment 1,793     2,040     1,880  
Legal and professional 783     2,052     1,535  
Data processing 1,252     1,460     1,354  
Marketing 1,006     986     1,062  
Amortization of intangibles 1,507     1,569     2,028  
FDIC insurance 512     495     448  
Communications 409     412     457  
Foreclosed assets, net 47     (35 )   138  
Other 1,156     2,822     2,141  
Total noninterest expense $ 27,700     $ 31,915     $ 30,001  
                       


Income Taxes

The effective income tax rate was 21.2% in the first quarter of 2021 compared to 19.6% in the linked quarter. The effective income tax rate in the first quarter of 2021 reflected an increase in income taxes based on the statutory rate and state income taxes, net of federal income tax benefits primarily due to the net income earned during the quarter, offset by benefits related to tax-exempt interest and bank-owned life insurance. The effective income tax rate for the full year 2021 is expected to be in the range of 20-22%.

   
BALANCE SHEET, LIQUIDITY AND CAPITAL HIGHLIGHTS
As of or For the Three Months Ended
  March 31,   December 31,   March 31,
(Dollars in millions, except per share amounts) 2021   2020   2020
Ending Balance Sheet          
Total assets $ 5,737.3     $ 5,556.6     $ 4,763.9  
Loans held for investment, net of unearned income 3,358.2     3,482.2     3,425.8  
Total securities held for investment 1,896.9     1,657.4     881.9  
Total deposits 4,794.6     4,547.0     3,859.8  
Average Balance Sheet          
Average total assets $ 5,520.3     $ 5,457.9     $ 4,669.7  
Average total loans 3,429.7     3,560.6     3,436.3  
Average total deposits 4,573.9     4,490.0     3,760.0  
Funding and Liquidity          
Short-term borrowings $ 175.8     $ 230.8     $ 129.5  
Long-term debt 201.7     208.7     209.9  
Loans to deposits ratio 70.04 %   76.58 %   88.75 %
Equity          
Total shareholders’ equity $ 511.3     $ 515.3     $ 500.6  
Common equity ratio 8.91 %   9.27 %   10.51 %
Tangible common equity(1) 425.1     427.5     376.4  
Tangible common equity ratio(1) 7.52 %   7.82 %   8.11 %
Per Share Data          
Book value $ 32.00     $ 32.17     $ 31.11  
Tangible book value(1) $ 26.60     $ 26.69     $ 23.39  
(1) Non-GAAP Measure. See the Non-GAAP Measures section for a reconciliation to the most directly comparable GAAP measure.


Loans Held for Investment

Loans held for investment, net of unearned income, decreased $124.1 million, or 4%, to $3.36 billion from December 31, 2020, driven primarily by net loan pay-downs and lower line utilization.

The following table presents the composition of loans held for investment, net of unearned income, as of the dates indicated:


Loans Held for Investment
March 31, 2021   December 31, 2020   March 31, 2020  
(dollars in thousands) Balance   % of
Total
  Balance   % of
Total
  Balance   % of
Total
 
Commercial and industrial $ 993,770     29.6   % $ 1,055,488     30.3   % $ 864,702     25.2   %
Agricultural 117,099     3.5     116,392     3.3     145,435     4.2    
Commercial real estate                        
Construction and development 164,927     4.9     181,291     5.2     282,921     8.3    
Farmland 138,199     4.1     144,970     4.2     168,777     4.9    
Multifamily 261,806     7.8     256,525     7.4     217,108     6.3    
Other 1,128,660     33.6     1,149,575     33.0     1,111,640     32.5    
Total commercial real estate 1,693,592     50.4     1,732,361     49.8     1,780,446     52.0    
Residential real estate                        
One-to-four family first liens 337,408     10.0     355,684     10.2     389,055     11.4    
One-to-four family junior liens 137,025     4.1     143,422     4.1     165,235     4.8    
Total residential real estate 474,433     14.1     499,106     14.3     554,290     16.2    
Consumer 79,267     2.4     78,876     2.3     80,889     2.4    
Loans held for investment, net of unearned income $ 3,358,161     100.0   % $ 3,482,223     100.0   % $ 3,425,762     100.0   %
                                           

Mr. Funk noted, “Loan demand remains weak in most areas of our geographic footprint. This is evidenced by credit line utilization of only 32% during the quarter compared to 46% in the first quarter of 2020. We believe loan demand will improve as the national economy opens up.”


Credit Loss Expense & Allowance for Credit Losses

The following table shows the activity in the allowance for credit losses for the periods indicated:

  Three Months Ended

Allowance for Credit Losses Roll Forward
March 31,   December 31,   March 31,
(In thousands) 2021   2020   2020
Beginning balance $ 55,500     $ 58,500     $ 29,079  
Cumulative effect of change in accounting principle – CECL         3,984  
Charge-offs (1,003 )   (1,005 )   (1,497 )
Recoveries 687     646     299  
Net charge-offs (316 )   (359 )   (1,198 )
Credit loss (benefit) expense related to loans (4,534 )   (2,641 )   19,322  
Ending balance $ 50,650     $ 55,500     $ 51,187  
                       

As of March 31, 2021, the allowance for credit losses (“ACL”) was $50.7 million, or 1.51% of loans held for investment, net of unearned income, compared with $55.5 million, or 1.59%, at December 31, 2020. After excluding net PPP loans, the ACL as a percentage of loans held for investment, net of unearned income, decreased to 1.63%(1) as of March 31, 2021, from 1.72%(1) at December 31, 2020. The decline in the ACL during the first quarter reflected overall improvements in the economic forecast and an improved credit profile outlook when compared to the linked quarter.

(
1)Non-GAAP Measure. See the Non-GAAPMeasures section for a reconciliation to the most directly comparable GAAP measure.

“We believe that our ACL is sufficient to weather the challenges that lie ahead,” stated Mr. Funk.


Deposits

The following table presents the composition of our deposit portfolio as of the dates indicated:


Deposit Composition
March 31, 2021   December 31, 2020   March 31, 2020  
(In thousands) Balance   % of Total   Balance   % of Total   Balance   % of Total  
Noninterest bearing deposits $ 958,526     20.0   % $ 910,655     20.0   % $ 637,127     16.5   %
Interest checking deposits 1,406,070     29.4     1,351,641     29.7     995,762     25.8    
Money market deposits 950,300     19.8     918,654     20.2     793,482     20.6    
Savings deposits 580,862     12.1     529,751     11.7     404,100     10.5    
Total non-maturity deposits 3,895,758     81.3     3,710,701     81.6     2,830,471     73.4    
Time deposits of $250,000 and under 558,338     11.6     581,471     12.8     688,409     17.8    
Time deposits over $250,000 340,467     7.1     254,877     5.6     340,964     8.8    
Total time deposits 898,805     18.7     836,348     18.4     1,029,373     26.6    
Total deposits $ 4,794,563     100.0   % $ 4,547,049     100.0   % $ 3,859,844     100.0   %
                                           

CREDIT RISK PROFILE

  As of or For the Three Months Ended

Highlights
March 31,   December 31,   March 31,
(dollars in thousands) 2021   2020   2020
Credit loss (benefit) expense related to loans $ (4,534 )     $ (2,641 )     $ 19,322  
Net charge-offs $ 316       $ 359       $ 1,198  
Net charge-off ratio(1) 0.04   %   0.04   %   0.14 %
           
At period-end          
Pass $ 3,112,728       $ 3,202,704       $ 3,231,725  
Special Mention / Watch 130,052       157,213       117,301  
Classified 115,381       122,306       76,736  
Total loans held for investment, net $ 3,358,161       $ 3,482,223       $ 3,425,762  
Classified loans ratio(2) 3.44   %   3.51   %   2.24 %
           
Nonaccrual loans held for investment $ 43,874       $ 41,950       $ 43,973  
Accruing loans contractually past due 90 days or more 508       739       303  
Total nonperforming loans 44,382       42,689       44,276  
Foreclosed assets, net 1,487       2,316       968  
Total nonperforming assets (3) $ 45,869       $ 45,005       $ 45,244  
Nonperforming loans ratio(4) 1.32   %   1.23   %   1.29 %
Nonperforming assets ratio(5) 0.80   %   0.81   %   0.95 %
Allowance for credit losses $ 50,650       $ 55,500       $ 51,187  
Allowance for credit losses ratio(6) 1.51   %   1.59   %   1.49 %
Adjusted allowance for credit losses ratio(7) 1.63   %   1.72   %   1.49 %
           
Performing troubled debt restructured loans held for investment $ 2,230       $ 2,630       $ 4,359  
(1) Net charge-off ratio is calculated as annualized net charge-offs divided by average loans held for investment, net of unearned income, during the period.
(2) Classified loans ratio is calculated as classified loans divided by loans held for investment, net of unearned income, at the end of the period.
(3) Starting in the second quarter of 2020, performing troubled debt restructured loans held for investment are no longer included in nonperforming assets. Prior period credit quality metrics have been adjusted to exclude these loans.
(4) Nonperforming loans ratio is calculated as total nonperforming loans divided by loans held for investment, net of unearned income, at the end of the period.
(5) Nonperforming assets ratio is calculated as total nonperforming assets divided by total assets at the end of the period.
(6) Allowance for credit losses ratio is calculated as allowance for credit losses divided by loans held for investment, net of unearned income, at the end of the period.
(7) Non-GAAP Measure. See the Non-GAAP Measures section for a reconciliation to the most directly comparable GAAP measure.
 

The following table presents a roll forward of nonperforming loans for the period indicated:


Nonperforming Loans
     
(dollars in thousands) Nonaccrual


  90+ Days Past Due
& Still Accruing



  Total
Balance at December 31, 2020 $ 41,950     $ 739     $ 42,689  
Loans placed on nonaccrual or 90+ days past due & still accruing 5,521     228     5,749  
Repayments (including interest applied to principal) (2,514 )   1     (2,513 )
Loans returned to accrual status or no longer past due (268 )   (330 )   (598 )
Charge-offs (715 )   (130 )   (845 )
Transfers to foreclosed assets (100 )       (100 )
Balance at March 31, 2021 $ 43,874     $ 508     $ 44,382  
                       

CAPITAL

Effective March 31, 2020, we elected the 5-year phase-in option allowed under the interim final rule (IFR) issued by the federal banking regulatory agencies that delays the estimated impact on regulatory capital stemming from the implementation of CECL. The IFR allows the add back of 100% of the capital effect from the day one CECL transition adjustment and 25% of the capital effect from subsequent increases in the allowance for credit losses through the two-year period ending December 31, 2021. This cumulative amount will then be reduced from capital over the subsequent three-year period.

  March 31,   December 31,   March 31,

Regulatory Capital Ratios
2021

(1)
  2020   2020
MidWest

One

Financial Group, Inc. Consolidated
         
Tier 1 leverage ratio 8.78 %   8.50 %   9.39 %
Common equity tier 1 capital ratio 10.16 %   9.72 %   9.25 %
Tier 1 capital ratio 11.13 %   10.70 %   10.25 %
Total capital ratio 13.75 %   13.41 %   11.48 %
MidWest

One

Bank
         
Tier 1 leverage ratio 9.60 %   9.35 %   10.03 %
Common equity tier 1 capital ratio 12.19 %   11.79 %   10.95 %
Tier 1 capital ratio 12.19 %   11.79 %   10.95 %
Total capital ratio 13.19 %   12.89 %   12.03 %
(1) Capital ratios for March 31, 2021 are preliminary          
           

CORPORATE UPDATE


Share Repurchase Program

During the first quarter of 2021, the Company repurchased 62,588 shares of its common stock at an average price of $27.14 per share and a total cost of $1.7 million. At March 31, 2021, $2.7 million remained available to repurchase shares under the Company’s current share repurchase program.

CONFERENCE CALL DETAILS

The Company will host a conference call for investors at 11:00 a.m. CT on Friday, April 23, 2021. To participate, please dial 866-233-3483 at least fifteen minutes before the call start time. If you are unable to participate on the call, a replay will be available until July 29, 2021, by calling 877-344-7529 and using the replay access code of 10153549. A transcript of the call will also be available on the Company’s web site (www.midwestonefinancial.com) within three business days of the call.

ABOUT MIDWEST

ONE

FINANCIAL GROUP, INC.

MidWestOne Financial Group, Inc. is a financial holding company headquartered in Iowa City, Iowa. MidWestOne is the parent company of MidWestOne Bank, which operates banking offices in Iowa, Minnesota, Wisconsin, Florida, and Colorado. MidWestOne provides electronic delivery of financial services through its website, MidWestOne.bank. MidWestOne Financial Group, Inc. trades on the Nasdaq Global Select Market under the symbol “MOFG”.


Cautionary Note Regarding Forward-Looking Statements

This release contains certain “forward-looking statements” within the meaning of such term in the Private Securities Litigation Reform Act of 1995. We and our representatives may, from time to time, make written or oral statements that are “forward-looking” and provide information other than historical information. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These factors include, among other things, the factors listed below. Forward-looking statements, which may be based upon beliefs, expectations and assumptions of our management and on information currently available to management, are generally identifiable by the use of words such as “believe,” “expect,” “anticipate,” “should,” “could,” “would,” “plans,” “goals,” “intend,” “project,” “estimate,” “forecast,” “may” or similar expressions. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, these statements. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Additionally, we undertake no obligation to update any statement in light of new information or future events, except as required under federal securities law.

Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors that could have an impact on our ability to achieve operating results, growth plan goals and future prospects include, but are not limited to, the following: (1) effects of the COVID-19 pandemic, including its potential effects on the economic environment, our customers and our operations, as well as any changes to federal, state, or local government laws, regulations, or orders in connection with the pandemic; (2) government intervention in the U.S. financial system in response to the COVID-19 pandemic, including the effects of recent legislative, tax, accounting and regulatory actions and reforms, including the Coronavirus Aid, Relief, and Economic Security Act, the Consolidated Appropriations Act, 2021 and the American Rescue Plan; (3) the impact of the COVID-19 pandemic on our financial results, including possible lost revenue and increased expenses (including the cost of capital), as well as possible goodwill impairment charges; (4) credit quality deterioration or pronounced and sustained reduction in real estate market values causing an increase in the allowance for credit losses, an increase in the credit loss expense, and a reduction in net earnings; (5) the effects of interest rates, including on our net income and the value of our securities portfolio; (6) changes in the economic environment, competition, or other factors that may affect our ability to acquire loans or influence the anticipated growth rate of loans and deposits and the quality of the loan portfolio and loan and deposit pricing; (7) fluctuations in the value of our investment securities; (8) governmental monetary and fiscal policies; (9) changes in and uncertainty related to benchmark interest rates used to price loans and deposits, including the expected elimination of LIBOR; (10) legislative and regulatory changes, including changes in banking, securities, trade, and tax laws and regulations and their application by our regulators; (11) the ability to attract and retain key executives and employees experienced in banking and financial services; (12) the sufficiency of the allowance for credit losses to absorb the amount of actual losses inherent in our existing loan portfolio; (13) our ability to adapt successfully to technological changes to compete effectively in the marketplace; (14) credit risks and risks from concentrations (by geographic area and by industry) within our loan portfolio; (15) the effects of competition from other commercial banks, thrifts, mortgage banking firms, consumer finance companies, credit unions, securities brokerage firms, insurance companies, money market and other mutual funds, financial technology companies, and other financial institutions operating in our markets or elsewhere or providing similar services; (16) the failure of assumptions underlying the establishment of allowances for credit losses and estimation of values of collateral and various financial assets and liabilities; (17) the risks of mergers, including, without limitation, the related time and costs of implementing such transactions, integrating operations as part of these transactions and possible failures to achieve expected gains, revenue growth and/or expense savings from such transactions; (18) volatility of rate-sensitive deposits; (19) operational risks, including data processing system failures or fraud; (20) asset/liability matching risks and liquidity risks; (21) the costs, effects and outcomes of existing or future litigation; (22) changes in general economic, political, or industry conditions, nationally, internationally or in the communities in which we conduct business; (23) changes in accounting policies and practices, as may be adopted by state and federal regulatory agencies and the Financial Accounting Standards Board; (24) war or terrorist activities, widespread disease or pandemic, or other adverse external events, which may cause deterioration in the economy or cause instability in credit markets; (25) the effects of cyber-attacks; (26) the imposition of tariffs or other domestic or international governmental policies impacting the value of the agricultural or other products of our borrowers; and (27) other risk factors detailed from time to time in Securities and Exchange Commission filings made by the Company.

 
MIDWEST

ONE

FINANCIAL GROUP, INC. AND SUBSIDIARIES

FIVE QUARTER CONSOLIDATED BALANCE SHEETS
                   
  March 31,   December 31,   September 30,   June 30,   March 31,
(In thousands) 2021   2020   2020   2020   2020
ASSETS                  
Cash and due from banks $ 57,154     $ 65,078     $ 71,901     $ 65,863     $ 60,396  
Interest earning deposits in banks 80,924     17,409     55,421     45,018     58,319  
Federal funds sold 7,691     172     7,540     6,329     6,830  
Total cash and cash equivalents 145,769     82,659     134,862     117,210     125,545  
Debt securities available for sale at fair value 1,896,894     1,657,381     1,366,344     1,187,455     881,859  
Loans held for sale 58,333     59,956     13,096     12,048     9,483  
Gross loans held for investment 3,374,076     3,496,790     3,555,969     3,618,675     3,440,907  
Unearned income, net (15,915 )   (14,567 )   (18,537 )   (21,636 )   (15,145 )
Loans held for investment, net of unearned income 3,358,161     3,482,223     3,537,432     3,597,039     3,425,762  
Allowance for credit losses (50,650 )   (55,500 )   (58,500 )   (55,644 )   (51,187 )
Total loans held for investment, net 3,307,511     3,426,723     3,478,932     3,541,395     3,374,575  
Premises and equipment, net 85,581     86,401     87,955     88,929     89,860  
Goodwill 62,477     62,477     62,477     93,977     93,977  
Other intangible assets, net 23,735     25,242     26,811     28,443     30,190  
Foreclosed assets, net 1,487     2,316     724     965     968  
Other assets 155,525     153,493     159,507     160,541     157,452  
Total assets $ 5,737,312     $ 5,556,648     $ 5,330,708     $ 5,230,963     $ 4,763,909  
LIABILITIES                   
Noninterest bearing deposits $ 958,526     $ 910,655     $ 864,504     $ 867,637     $ 637,127  
Interest bearing deposits 3,836,037     3,636,394     3,469,137     3,397,798     3,222,717  
Total deposits 4,794,563     4,547,049     4,333,641     4,265,435     3,859,844  
Short-term borrowings 175,785     230,789     183,893     162,224     129,489  
Long-term debt 201,696     208,691     245,481     189,973     209,874  
Other liabilities 53,948     54,869     68,612     92,550     64,138  
Total liabilities 5,225,992     5,041,398     4,831,627     4,710,182     4,263,345  
SHAREHOLDERS’ EQUITY                   
Common stock 16,581     16,581     16,581     16,581     16,581  
Additional paid-in capital 299,747     300,137     299,939     299,542     299,412  
Retained earnings 206,230     188,191     175,017     198,382     190,212  
Treasury stock (15,278 )   (14,251 )   (12,272 )   (12,272 )   (12,518 )
Accumulated other comprehensive income 4,040     24,592     19,816     18,548     6,877  
Total shareholders’ equity 511,320     515,250     499,081     520,781     500,564  
Total liabilities and shareholders’ equity $ 5,737,312     $ 5,556,648     $ 5,330,708     $ 5,230,963     $ 4,763,909  
                                       

 
MIDWEST

ONE

FINANCIAL GROUP, INC. AND SUBSIDIARIES

FIVE QUARTER CONSOLIDATED STATEMENTS OF INCOME
   
  Three Months Ended
  March 31,   December 31,   September 30,   June 30,   March 31,
(In thousands, except per share data) 2021   2020   2020   2020   2020
Interest income                  
Loans, including fees $ 36,542     $ 38,239     $ 38,191     $ 40,214     $ 42,012  
Taxable investment securities 5,093     4,673     4,574     4,646     3,717  
Tax-exempt investment securities 2,555     2,529     2,360     1,858     1,512  
Other 14     29     29     40     164  
Total interest income 44,204     45,470     45,154     46,758     47,405  
Interest expense                  
Deposits 3,608     4,265     5,296     6,409     7,949  
Short-term borrowings 128     142     175     263     334  
Long-term debt 1,851     2,026     1,874     1,374     1,716  
Total interest expense 5,587     6,433     7,345     8,046     9,999  
Net interest income 38,617     39,037     37,809     38,712     37,406  
Credit loss (benefit) expense (4,734 )   (3,041 )   4,992     4,685     21,733  
Net interest income after credit loss (benefit) expense 43,351     42,078     32,817     34,027     15,673  
Noninterest income                  
Investment services and trust activities 2,836     2,518     2,361     2,217     2,536  
Service charges and fees 1,487     1,571     1,491     1,290     1,826  
Card revenue 1,536     1,517     1,600     1,237     1,365  
Loan revenue 4,730     3,900     3,252     1,910     1,123  
Bank-owned life insurance 542     541     530     635     520  
Investment securities gains, net 27     30     106     6     42  
Other 666     549     230     974     2,743  
Total noninterest income 11,824     10,626     9,570     8,269     10,155  
Noninterest expense                  
Compensation and employee benefits 16,917     17,638     16,460     15,682     16,617  
Occupancy expense of premises, net 2,318     2,476     2,278     2,253     2,341  
Equipment 1,793     2,040     1,935     2,010     1,880  
Legal and professional 783     2,052     1,184     1,382     1,535  
Data processing 1,252     1,460     1,308     1,240     1,354  
Marketing 1,006     986     857     910     1,062  
Amortization of intangibles 1,507     1,569     1,631     1,748     2,028  
FDIC insurance 512     495     470     445     448  
Communications 409     412     428     449     457  
Foreclosed assets, net 47     (35 )   13     34     138  
Goodwill impairment         31,500          
Other 1,156     2,822     1,875     1,885     2,141  
Total noninterest expense 27,700     31,915     59,939     28,038     30,001  
Income (loss) before income tax expense 27,475     20,789     (17,552 )   14,258     (4,173 )
Income tax expense (benefit) 5,827     4,079     2,272     2,546     (2,198 )
Net income (loss) $ 21,648     $ 16,710     $ (19,824 )   $ 11,712     $ (1,975 )
                   
Earnings (loss) per common share                  
Basic $ 1.35     $ 1.04     $ (1.23 )   $ 0.73     $ (0.12 )
Diluted $ 1.35     $ 1.04     $ (1.23 )   $ 0.73     $ (0.12 )
Weighted average basic common shares outstanding 15,991     16,074     16,099     16,094     16,142  
Weighted average diluted common shares outstanding 16,021     16,092     16,099     16,100     16,142  
Dividends paid per common share $ 0.2250     $ 0.2200     $ 0.2200     $ 0.2200     $ 0.2200  
                                       

 
MIDWEST

ONE

FINANCIAL GROUP, INC. AND SUBSIDIARIES

FINANCIAL STATISTICS
   
  As of or for the three months ended
  March 31,   December 31,   March 31,
(Dollars in thousands, except per share amounts) 2021   2020   2020

Earnings:
         
Net interest income $ 38,617       $ 39,037       $ 37,406    
Noninterest income 11,824       10,626       10,155    
Total revenue, net of interest expense 50,441       49,663       47,561    
Credit loss (benefit) expense (4,734 )     (3,041 )     21,733    
Noninterest expense 27,700       31,915       30,001    
Income (loss) before income tax expense (benefit) 27,475       20,789       (4,173 )  
Income tax expense (benefit) 5,827       4,079       (2,198 )  
Net income (loss) $ 21,648       $ 16,710       $ (1,975 )  

Per Share Data:
         
Diluted earnings (loss) $ 1.35       $ 1.04       $ (0.12 )  
Book value 32.00       32.17       31.11    
Tangible book value(1) 26.60       26.69       23.39    

Ending Balance Sheet:
         
Total assets $ 5,737,312       $ 5,556,648       $ 4,763,909    
Loans held for investment, net of unearned income 3,358,161       3,482,223       3,425,762    
Total securities held for investment 1,896,894       1,657,381       881,859    
Total deposits 4,794,563       4,547,049       3,859,844    
Short-term borrowings 175,785       230,789       129,489    
Long-term debt 201,696       208,691       209,874    
Total shareholders’ equity 511,320       515,250       500,564    

Average Balance Sheet:
         
Average total assets $ 5,520,304       $ 5,457,939       $ 4,669,724    
Average total loans 3,429,746       3,560,632       3,436,263    
Average total deposits 4,573,898       4,490,048       3,760,016    

Financial Ratios:
         
Return on average assets 1.59   %   1.22   %   (0.17 ) %
Return on average equity 17.01   %   13.15   %   (1.54 ) %
Return on average tangible equity(1) 21.52   %   17.07   %   (0.47 ) %
Efficiency ratio(1) 50.77   %   59.69   %   57.67   %
Net interest margin, tax equivalent(1) 3.10   %   3.13   %   3.60   %
Loans to deposits ratio 70.04   %   76.58   %   88.75   %
Common equity ratio 8.91   %   9.27   %   10.51   %
Tangible common equity ratio(1) 7.52   %   7.82   %   8.11   %

Credit Risk Profile:
         
Total nonperforming loans $ 44,382       $ 42,689       $ 44,276    
Nonperforming loans ratio 1.32   %   1.23   %   1.29   %
Total nonperforming assets $ 45,869       $ 45,005       $ 45,244    
Nonperforming assets ratio 0.80   %   0.81   %   0.95   %
Performing troubled debt restructured loans held for investment $ 2,230       $ 2,630       $ 4,359    
Net charge-offs $ 316       $ 359       $ 1,198    
Net charge-off ratio 0.04   %   0.04   %   0.14   %
Allowance for credit losses $ 50,650       $ 55,500       $ 51,187    
Allowance for credit losses ratio 1.51   %   1.59   %   1.49   %
Adjusted allowance for credit losses ratio(1) 1.63   %   1.72   %   1.49   %

PPP Loans:
         
Average PPP loans $ 236,231       $ 313,252          
Fee Income 4,377       3,059          
           
(1) Non-GAAP measure. See the Non-GAAP Measures section for a reconciliation to the most directly comparable GAAP measure.
 

 
MIDWEST

ONE

FINANCIAL GROUP, INC. AND SUBSIDIARIES

AVERAGE BALANCE SHEET AND YIELD ANALYSIS
   
  Three Months Ended
  March 31, 2021   December 31, 2020   March 31, 2020
(Dollars in thousands) Average

Balance
  Interest

Income/

Expense
  Average

Yield/

Cost
  Average

Balance
  Interest

Income/

Expense
  Average

Yield/

Cost
  Average
Balance
  Interest

Income/

Expense
  Average

Yield/

Cost
ASSETS                                  
Loans, including fees (1)(2)(3) $ 3,429,746     $ 37,073     4.38 %   $ 3,560,632     $ 38,795     4.33 %   $ 3,436,263     $ 42,509     4.98 %
Taxable investment securities 1,266,714     5,093     1.63 %   1,026,359     4,673     1.81 %   567,001     3,717     2.64 %
Tax-exempt investment securities (2)(4) 465,793     3,203     2.79 %   450,659     3,180     2.81 %   224,171     1,907     3.42 %
Total securities held for investment(2) 1,732,507     8,296     1.94 %   1,477,018     7,853     2.12 %   791,172     5,624     2.86 %
Other 36,536     14     0.16 %   80,019     29     0.14 %   55,833     164     1.18 %
Total interest earning assets(2) $ 5,198,789     45,383     3.54 %   $ 5,117,669     46,677     3.63 %   $ 4,283,268     48,297     4.54 %
Other assets 321,515             340,270             386,456          
Total assets $ 5,520,304             $ 5,457,939             $ 4,669,724          
LIABILITIES AND SHAREHOLDERS’ EQUITY                                  
Interest checking deposits $ 1,349,671     $ 991     0.30 %   $ 1,276,320     $ 958     0.30 %   $ 965,077     $ 1,316     0.55 %
Money market deposits 913,087     478     0.21 %   931,900     544     0.23 %   766,766     1,645     0.86 %
Savings deposits 553,824     286     0.21 %   508,763     279     0.22 %   393,833     391     0.40 %
Time deposits 837,460     1,853     0.90 %   862,408     2,484     1.15 %   997,136     4,597     1.85 %
Total interest bearing deposits 3,654,042     3,608     0.40 %   3,579,391     4,265     0.47 %   3,122,812     7,949     1.02 %
Short-term borrowings 175,193     128     0.30 %   182,080     142     0.31 %   121,942     334     1.10 %
Long-term debt 205,971     1,851     3.64 %   223,407     2,026     3.61 %   225,587     1,716     3.06 %
Total borrowed funds 381,164     1,979     2.11 %   405,487     2,168     2.13 %   347,529     2,050     2.37 %
Total interest bearing liabilities $ 4,035,206     $ 5,587     0.56 %   $ 3,984,878     $ 6,433     0.64 %   $ 3,470,341     $ 9,999     1.16 %
Noninterest bearing deposits 919,856             910,657             637,204          
Other liabilities 49,003             56,898             47,010          
Shareholders’ equity 516,239             505,506             515,169          
Total liabilities and shareholders’ equity $ 5,520,304             $ 5,457,939             $ 4,669,724          
Net interest income(2)     $ 39,796             $ 40,244             $ 38,298      
Net interest spread(2)         2.98 %           2.99 %           3.38 %
Net interest margin(2)         3.10 %           3.13 %           3.60 %
                                   
Total deposits(5) $ 4,573,898     $ 3,608     0.32 %   $ 4,490,048     $ 4,265     0.38 %   $ 3,760,016     $ 7,949     0.85 %
Cost of funds(6)         0.46 %           0.52 %           0.98 %

(1) Average balance includes nonaccrual loans.
(2) Tax equivalent. The federal statutory tax rate utilized was 21%.
(3) Interest income includes net loan fees, loan purchase discount accretion and tax equivalent adjustments. Net loan fees were $3.5 million, $2.5 million, and $(122) thousand for the three months ended March 31, 2021, December 31, 2020, and March 31, 2020, respectively. Loan purchase discount accretion was $1.1 million, $1.5 million, and $3.0 million for the three months ended March 31, 2021, December 31, 2020, and March 31, 2020, respectively. Tax equivalent adjustments were $531 thousand, $556 thousand, and $497 thousand for the three months ended March 31, 2021, December 31, 2020, and March 31, 2020, respectively. The federal statutory tax rate utilized was 21%.
(4) Interest income includes tax equivalent adjustments of $648 thousand, $651 thousand, and $395 thousand for the three months ended March 31, 2021, December 31, 2020, and March 31, 2020, respectively. The federal statutory tax rate utilized was 21%.
(5) Total deposits is the sum of total interest-bearing deposits and noninterest bearing deposits. The cost of total deposits is calculated as annualized interest expense on deposits divided by average total deposits.
(6) Cost of funds is calculated as annualized total interest expense divided by the sum of average total deposits and borrowed funds.

Non-GAAP Measures

This earnings release contains non-GAAP measures for tangible common equity, tangible book value per share, tangible common equity ratio, return on average tangible equity, net interest margin (tax equivalent), core net interest margin, loan yield (tax equivalent), core yield on loans, efficiency ratio, adjusted allowance for credit losses ratio, core loans, and core commercial loans. Management believes these measures provide investors with useful information regarding the Company’s profitability, financial condition and capital adequacy, consistent with how management evaluates the Company’s financial performance. The following tables provide a reconciliation of each non-GAAP measure to the most comparable GAAP measure.

                     
Tangible Common Equity/Tangible Book Value                    
per Share/Tangible Common Equity Ratio   March 31,   December 31,   September 30,   June 30,   March 31,
(Dollars in thousands, except per share data)   2021   2020   2020   2020   2020
Total shareholders’ equity   $ 511,320       $ 515,250       $ 499,081       $ 520,781       $ 500,564    
Intangible assets, net   (86,212 )     (87,719 )     (89,288 )     (122,420 )     (124,167 )  
Tangible common equity   $ 425,108       $ 427,531       $ 409,793       $ 398,361       $ 376,397    
                     
Total assets   $ 5,737,312       $ 5,556,648       $ 5,330,708       $ 5,230,963       $ 4,763,909    
Intangible assets, net   (86,212 )     (87,719 )     (89,288 )     (122,420 )     (124,167 )  
Tangible assets   $ 5,651,100       $ 5,468,929       $ 5,241,420       $ 5,108,543       $ 4,639,742    
                     
Book value per share   $ 32.00       $ 32.17       $ 31.00       $ 32.35       $ 31.11    
Tangible book value per share(1)   $ 26.60       $ 26.69       $ 25.45       $ 24.74       $ 23.39    
Shares outstanding   15,981,088       16,016,780       16,099,324       16,099,324       16,089,782    
                     
Common equity ratio   8.91   %   9.27   %   9.36   %   9.96   %   10.51   %
Tangible common equity ratio(2)   7.52   %   7.82   %   7.82   %   7.80   %   8.11   %

(1) Tangible common equity divided by shares outstanding.
(2) Tangible common equity divided by tangible assets.

     
    Three Months Ended
Return on Average Tangible Equity   March 31,   December 31,   March 31,
(Dollars in thousands)   2021   2020   2020
Net income (loss)   $ 21,648       $ 16,710       $ (1,975 )  
Intangible amortization, net of tax(1)   1,130       1,177       1,521    
Tangible net income (loss)   $ 22,778       $ 17,887       $ (454 )  
             
Average shareholders’ equity   $ 516,239       $ 505,506       $ 515,169    
Average intangible assets, net   (86,961 )     (88,543 )     (122,948 )  
Average tangible equity   $ 429,278       $ 416,963       $ 392,221    
             
Return on average equity   17.01   %   13.15   %   (1.54 ) %
Return on average tangible equity(2)   21.52   %   17.07   %   (0.47 ) %

(1) The combined income tax rate utilized was 25%.
(2) Annualized tangible net income divided by average tangible equity.

     
Net Interest Margin, Tax Equivalent/
  Three Months Ended
Core Net Interest Margin   March 31,   December 31,   March 31,
(Dollars in thousands)   2021   2020   2020
Net interest income   $ 38,617       $ 39,037       $ 37,406    
Tax equivalent adjustments:            
Loans(1)   531       556       497    
Securities(1)   648       651       395    
Net interest income, tax equivalent   $ 39,796       $ 40,244       $ 38,298    
Loan purchase discount accretion   (1,098 )     (1,542 )     (3,023 )  
Core net interest income   $ 38,698       $ 38,702       $ 35,275    
             
Net interest margin   3.01   %   3.03   %   3.51   %
Net interest margin, tax equivalent(2)   3.10   %   3.13   %   3.60   %
Core net interest margin(3)   3.02   %   3.01   %   3.31   %
Average interest earning assets   $ 5,198,789       $ 5,117,669       $ 4,283,268    

(1) The federal statutory tax rate utilized was 21%.
(2) Annualized tax equivalent net interest income divided by average interest earning assets.
(3) Annualized core net interest income divided by average interest earning assets.

     
    Three Months Ended
Loan Yield, Tax Equivalent / Core Yield on Loans   March 31,   December 31,   March 31,
(Dollars in thousands)   2021   2020   2020
Loan interest income, including fees   $ 36,542       $ 38,239       $ 42,012    
Tax equivalent adjustment(1)   531       556       497    
Tax equivalent loan interest income   $ 37,073       $ 38,795       $ 42,509    
Loan purchase discount accretion   (1,098 )     (1,542 )     (3,023 )  
Core loan interest income   $ 35,975       $ 37,253       $ 39,486    
             
Yield on loans   4.32   %   4.27   %   4.92   %
Yield on loans, tax equivalent(2)   4.38   %   4.33   %   4.98   %
Core yield on loans(3)   4.25   %   4.16   %   4.62   %
Average loans   $ 3,429,746       $ 3,560,632       $ 3,436,263    

(1) The federal statutory tax rate utilized was 21%.
(2) Annualized tax equivalent loan interest income divided by average loans.
(3) Annualized core loan interest income divided by average loans.

     
    Three Months Ended
Efficiency Ratio   March 31,   December 31,   March 31,
(Dollars in thousands)   2021   2020   2020
Total noninterest expense   $ 27,700       $ 31,915       $ 30,001    
Amortization of intangibles   (1,507 )     (1,569 )     (2,028 )  
Merger-related expenses               (54 )  
Noninterest expense used for efficiency ratio   $ 26,193       $ 30,346       $ 27,919    
             
Net interest income, tax equivalent(1)   $ 39,796       $ 40,244       $ 38,298    
Noninterest income   11,824       10,626       10,155    
Investment securities gains, net   (27 )     (30 )     (42 )  
Net revenues used for efficiency ratio   $ 51,593       $ 50,840       $ 48,411    
             
Efficiency ratio (2)   50.77   %   59.69   %   57.67   %

(1) The federal statutory tax rate utilized was 21%.
(2) Noninterest expense adjusted for amortization of intangibles and merger-related expenses divided by the sum of tax equivalent net interest income, noninterest income and net investment securities gains.

                     
Adjusted Allowance for Credit Losses Ratio   March 31,   December 31,   September 30,   June 30,   March 31,
(Dollars in thousands)   2021   2020   2020   2020   2020
Loans held for investment, net of unearned income   $ 3,358,161       $ 3,482,223       $ 3,537,432       $ 3,597,039       $ 3,425,762  
PPP loans   (248,682 )     (259,260 )     (331,703 )     (327,648 )      
Core loans   $ 3,109,479       $ 3,222,963       $ 3,205,729       $ 3,269,391       $ 3,425,762  
Allowance for credit losses   $ 50,650       $ 55,500       $ 58,500       $ 55,644       $ 51,187  
                     
Allowance for credit losses ratio   1.51   %   1.59   %   1.65   %   1.55   %   1.49 %
Adjusted allowance for credit losses ratio(1)   1.63   %   1.72   %   1.82   %   1.70   %   1.49 %

(1) Allowance for credit losses divided by core loans

                     
Core Loans/Core Commercial Loans   March 31,   December 31,   September 30,   June 30,   March 31,
(Dollars in thousands)   2021   2020   2020   2020   2020

Commercial loans:
                   
Commercial and industrial   $ 993,770     $ 1,055,488     $ 1,103,102     $ 1,084,527     $ 864,702  
Agricultural   117,099     116,392     129,453     140,837     145,435  
Commercial real estate   1,693,592     1,732,361     1,707,035     1,764,739     1,780,446  
Total commercial loans   $ 2,804,461     $ 2,904,241     $ 2,939,590     $ 2,990,103     $ 2,790,583  

Consumer loans:
                   
Residential real estate   $ 474,433     $ 499,106     $ 521,570     $ 532,914     $ 554,290  
Other consumer   79,267     78,876     76,272     74,022     80,889  
Total consumer loans   $ 553,700     $ 577,982     $ 597,842     $ 606,936     $ 635,179  
Loans held for investment, net of unearned income   $ 3,358,161     $ 3,482,223     $ 3,537,432     $ 3,597,039     $ 3,425,762  
                     
PPP loans   $ 248,682     $ 259,260     $ 331,703     $ 327,648     $  
                     
Core loans(1)   $ 3,109,479     $ 3,222,963     $ 3,205,729     $ 3,269,391     $ 3,425,762  
Core commercial loans(2)   $ 2,555,779     $ 2,644,981     $ 2,607,887     $ 2,662,455     $ 2,790,583  

(1) Core loans are calculated as loans held for investment, net of unearned income less PPP loans.
(2) Core commercial loans are calculated as total commercial loans less PPP loans.

Category: Earnings

This news release may be downloaded from https://www.midwestonefinancial.com/corporate-profile/default.aspx

Source: MidWestOne Financial Group, Inc.

Contact:
   
  Charles N. Funk   Barry S. Ray
  Chief Executive Officer   Senior Executive Vice President and Chief Financial Officer
  319.356.5800   319.356.5800



FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer

– GARNET study represents the largest dataset of anti-PD-1 monotherapy treatment of women with endometrial cancer

– Study results showed an overall response rate of 42%

– 93% of responders had a duration of response of ≥6 months

PR Newswire

LONDON, April 22, 2021 /PRNewswire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company’s Biologics License Application. JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that have progressed on or following prior treatment with a platinum-containing regimen. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 

Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Unfortunately, as many as 60,000 women are diagnosed with endometrial cancer in the US each year and these women currently have limited treatment options if their disease progresses on or after first-line therapy. Today’s approval of JEMPERLI by the FDA has the potential to transform the treatment landscape for these women and demonstrates our continued commitment to helping patients with gynecologic cancers.”

Around 1 in 4 women with endometrial cancer may experience a recurrence or be diagnosed with advanced disease.i,ii For women whose disease recurs after platinum-based chemotherapy, there is generally no accepted standard of care.iii,iv,v Additionally, endometrial cancer has the highest rate of dMMR among tumor typesvi,vii at approximately 25%,vii and increased rates of recurrence have been reported for women with dMMR endometrial cancer.viii

Dr Jubilee Brown, Professor and Division Director of Gynecologic Oncology at Levine Cancer Institute, Atrium Health, and investigator on the GARNET study, noted: “The approval of JEMPERLI has the potential to change the way we’ve been treating dMMR advanced or recurrent endometrial cancer after standard platinum-based chemotherapy, especially given the overall response rate and durability of response that we saw in the GARNET trial.”

The approval is based on results from the dMMR endometrial cancer cohort of the ongoing GARNET trial, a large, multicenter, non-randomized, multiple parallel-cohort, open-label study, representing the largest dataset to date evaluating an anti-PD-1 antibody as monotherapy treatment in women with endometrial cancer.v The approval was granted under the FDA’s Real-Time Oncology Review pilot program, and JEMPERLI was initially granted breakthrough therapy designation in May of 2019 for recurrent or advanced dMMR endometrial cancer. 

The primary endpoints in the GARNET trial were overall response rate (ORR) and duration of response (DOR) as assessed by blinded independent central review (BICR). Results showed an ORR of 42.3% (95% CI; 30.6-54.6) with a complete response (CR) rate of 12.7% and partial response rate (PR) of 29.6% among the 71 evaluable patients with dMMR advanced or recurrent endometrial cancer who had progressed on or after treatment with a platinum-containing regimen. Of those that responded, 93.3% demonstrated a DOR of 6 months or more. After a median follow-up of 14.1 months, the median duration of response was not reached (2.6-22.4+).

Patients received 500 mg of JEMPERLI as an intravenous infusion once every three weeks for four doses, followed by 1,000 mg once every six weeks until disease progression or unacceptable toxicity. Among the 104 patients evaluable for safety, the most commonly reported adverse reactions (occurring in 20% or more of patients) were fatigue/asthenia (48%), nausea (30%), diarrhea (26%), anemia (24%) and constipation (20%). The most common Grade 3 or 4 adverse reactions (≥2%) were anemia and transaminases increase. JEMPERLI was permanently discontinued due to adverse reactions in 5 (4.8%) patients. No deaths attributed to JEMPERLI were reported in the study.

Dr Sue Friedman, Executive Director of Facing Our Risk of Cancer Empowered (FORCE),
commented: “We applaud GSK and their ongoing efforts to support women with endometrial cancer, the most common gynecologic malignancy in the US and the sixth most common cancer in women worldwide. For many women whose disease is dMMR and has progressed after platinum-based chemotherapy, the approval of JEMPERLI brings a new treatment option to an underserved patient population.”

GSK is also studying JEMPERLI for endometrial cancer in earlier treatment lines and in combination with other therapeutic agents for patients with advanced solid tumors or metastatic cancer as we work to expand our oncology pipeline and reinforce our portfolio of cancer treatments.

Making our products affordable and accessible
GSK is actively involved in creating solutions that allow patients to have access to new scientific breakthroughs. We remain committed to helping patients access GSK medications and have a long history of providing patient assistance programs. Patients and healthcare professionals can access more information about our oncology specific resources on insurance coverage and financial support at: www.TogetherwithGSKOncology.com or call: 1-844-4GSK-ONC (1-844-447-5662).

About Endometrial Cancer
Endometrial cancer is a main type of uterine cancer that forms in the inner lining of the uterus, known as the endometrium.ix Endometrial cancer can be classified as mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) or mismatch repair-proficient/microsatellite stable. There are limited treatment options for women whose disease progresses on or after first-line therapy.ix Nearly 60,000 new cases of endometrial cancer are expected in the US in 2021, making endometrial cancer the most common gynecologic malignancy in the US.x,xi Approximately 25% of women with endometrial cancer will be diagnosed with advanced disease or will experience a recurrence.i,ii  

About GARNET
The ongoing phase I GARNET trial is evaluating dostarlimab as monotherapy in patients with advanced solid tumors. Part 2B of the study includes five expansion cohorts: dMMR/MSI-H endometrial cancer (cohort A1), mismatch repair proficient/microsatellite stable (MMRp/MSS) endometrial cancer (cohort A2), non-small cell lung cancer (cohort E), dMMR/MSI-H non-endometrial or POLE-mut solid tumor basket cohort (cohort F), and platinum-resistant ovarian cancer without BRCA mutations (cohort G). GARNET is still enrolling patients.

About JEMPERLI (dostarlimab-gxly)
JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.xiii In addition to GARNET, JEMPERLI is being investigated in other registrational enabling studies, as monotherapy and as part of combination regimens for women with recurrent or primary advanced endometrial cancer stage III or IV non-mucinous epithelial ovarian cancer for patients with advanced solid tumors or metastatic cancer.

JEMPERLI was discovered by AnaptysBio and licensed to TESARO, Inc., under a Collaboration and Exclusive License Agreement signed in March 2014. The collaboration has resulted in three monospecific antibody therapies that have progressed into the clinic. These are: JEMPERLI (GSK4057190), a PD-1 antagonist; cobolimab, (GSK4069889), a TIM-3 antagonist; and GSK4074386, a LAG-3 antagonist. GSK is responsible for the ongoing research, development, commercialization, and manufacture of each of these Products under the Agreement.

Important Safety Information for JEMPERLI

Immune-Mediated Adverse Reactions

  • Immune-mediated adverse reactions, which can be severe or fatal, can occur in any organ system or tissue and can occur at any time during or after treatment with a PD-1/PD-L1–blocking antibody, including JEMPERLI.
  • Monitor closely for signs and symptoms of immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function tests at baseline and periodically during treatment. For suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
  • Based on the severity of the adverse reaction, withhold or permanently discontinue JEMPERLI. In general, if JEMPERLI requires interruption or discontinuation, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone or equivalent) until improvement to ≤Grade 1. Upon improvement to ≤Grade 1, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reaction is not controlled with corticosteroids.

Immune-Mediated Pneumonitis

  • JEMPERLI can cause immune-mediated pneumonitis, which can be fatal. The incidence of pneumonitis in patients receiving PD-1/PD-L1 inhibitors, including JEMPERLI, may be increased in patients who have received prior thoracic radiation.
  • Immune-mediated pneumonitis occurred in 1.1% (5/444) of patients, including Grade 2 (0.9%) and Grade 3 (0.2%) pneumonitis. Pneumonitis led to discontinuation of JEMPERLI in 0.7% of patients. Systemic corticosteroids were required in all patients with pneumonitis. Pneumonitis resolved in 80% of the 5 patients. Three patients reinitiated JEMPERLI after symptom improvement; of these, 33% had recurrence of pneumonitis.

Immune-Mediated Colitis

  • JEMPERLI can cause immune-mediated colitis. Cytomegalovirus infection/reactivation occurred in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1/PD-L1–blocking antibodies. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.
  • Immune-mediated colitis occurred in 1.4% (6/444) of patients, including Grade 3 (0.7%) and Grade 2 (0.7%). Colitis did not lead to discontinuation of JEMPERLI in any patients. Systemic corticosteroids were required in 17% (1/6) of patients with colitis. Colitis resolved in 50% of the 6 patients. Of the 2 patients in whom JEMPERLI was withheld for colitis, both reinitiated JEMPERLI.

Immune-Mediated Hepatitis

  • JEMPERLI can cause immune-mediated hepatitis, which can be fatal. Immune-mediated Grade 3 hepatitis occurred in 0.2% (1/444) of patients. Systemic corticosteroids were required, and the event resolved.

Immune-Mediated Endocrinopathies

  • Adrenal Insufficiency
    • JEMPERLI can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Withhold JEMPERLI if not clinically stable. Adrenal insufficiency occurred in 0.9% (4/444) of patients, including Grade 3 (0.5%) and Grade 2 (0.5%). Adrenal insufficiency resulted in discontinuation in 1 (0.2%) patient and resolved in 25% of the 4 patients.
  • Hypophysitis
    • JEMPERLI can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold JEMPERLI if not clinically stable.
  • Thyroid Disorders
    • JEMPERLI can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement or medical management of hyperthyroidism as clinically indicated. Withhold JEMPERLI if not clinically stable.
    • Thyroiditis occurred in 0.5% (2/444) of patients; both were Grade 2. Neither event of thyroiditis resolved; there were no discontinuations of JEMPERLI due to thyroiditis.
    • Hypothyroidism occurred in 5.6% (25/444) of patients, all of which were Grade 2. Hypothyroidism did not lead to discontinuation of JEMPERLI and resolved in 40% of the 25 patients. Systemic corticosteroids were not required for any of the 25 patients with hypothyroidism.
    • Hyperthyroidism occurred in 1.8% (8/444) of patients, including Grade 2 (1.6%) and Grade 3 (0.2%). Hyperthyroidism did not lead to discontinuation of JEMPERLI and resolved in 63% of the 8 patients. Systemic corticosteroids were not required for any of the 8 patients with hyperthyroidism.
  • Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis
    • JEMPERLI can cause type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity.

Immune-Mediated Nephritis with Renal Dysfunction

  • JEMPERLI can cause immune-mediated nephritis, which can be fatal. Nephritis occurred in 0.5% (2/444) of patients; both were Grade 2. Nephritis did not lead to discontinuation of JEMPERLI and resolved in both patients. Systemic corticosteroids were required in 1 of the 2 patients experiencing nephritis.

Immune-Mediated Dermatologic Adverse Reactions

  • JEMPERLI can cause immune-mediated rash or dermatitis. Bullous and exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), have occurred with PD-1/PD-L1–blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes. Withhold or permanently discontinue JEMPERLI depending on severity.

Other Immune-Mediated Adverse Reactions

  • The following clinically significant immune-mediated adverse reactions occurred in <1% of the 444 patients treated with JEMPERLI or were reported with the use of other PD-1/PD-L1–blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.
    • Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain-Barre syndrome, nerve paresis, autoimmune neuropathy
    • Cardiac/Vascular: Myocarditis, pericarditis, vasculitis
    • Ocular: Uveitis, iritis, other ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur.
    • Gastrointestinal: Pancreatitis, including increases in serum amylase and lipase levels, gastritis, duodenitis
    • Musculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatica
    • Endocrine: Hypoparathyroidism
    • Other (Hematologic/Immune): Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection

Infusion-Related Reactions

  • Severe or life-threatening infusion-related reactions have been reported with PD-1/PD-L1–blocking antibodies. Severe infusion-related reactions (Grade 3) occurred in 0.2% (1/444) of patients receiving JEMPERLI. All patients recovered from the infusion-related reactions.
  • Monitor patients for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion or permanently discontinue JEMPERLI based on severity of reaction.

Complications of Allogeneic HSCT after PD-1/PD-L1–Blocking Antibody:

  • Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after treatment with a PD-1/PD-L1–blocking antibody. These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1–blocking antibody prior to or after an allogeneic HSCT.

Embryo-Fetal Toxicity and Lactation:

  • Based on its mechanism of action, JEMPERLI can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JEMPERLI and for 4 months after their last dose. Because of the potential for serious adverse reactions from JEMPERLI in a breastfed child, advise women not to breastfeed during treatment with JEMPERLI and for 4 months after their last dose.

Common Adverse Reactions

  • The most common adverse reactions (Grades 1-4) in ≥10% of 104 dMMR endometrial cancer patients who received JEMPERLI as monotherapy were fatigue (48%), nausea (30%), diarrhea (26%), anemia (24%), constipation (20%), vomiting (18%), pruritus (14%), cough (14%), decreased appetite (14%), urinary tract infection (13%), and myalgia (12%).
  • JEMPERLI was permanently discontinued due to adverse reactions in 5 (4.8%) patients, including transaminases increased, sepsis, bronchitis, and pneumonitis. Dosage interruptions due to an adverse reaction occurred in 23% of patients who received JEMPERLI. Adverse reactions that required dosage interruption in ≥1% of patients who received JEMPERLI were anemia, diarrhea, increased lipase, and pyrexia.

Please see full

Prescribing Information

GSK in Oncology
GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.

About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/en-gb/about-us/.


GSK enquiries:

Media enquiries:

Simon Steel

+44 (0) 20 8047 5502

(London)

Tim Foley

+44 (0) 20 8047 5502

(London)

Kristen Neese

+1 804 217 8147

(Philadelphia)

Kathleen Quinn

+1 202 603 5003

(Washington DC)

Analyst/Investor enquiries:

James Dodwell

+44 (0) 20 8047 2406

(London)

Sonya Ghobrial

+44 (0) 7392 784784

(Consumer)

Mick Readey

+44 (0) 7990 339653

(London)

Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

Frannie DeFranco

+1 215 751 4855

(Philadelphia)

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company’s Annual Report on Form 20-F for 2020 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS


i CancerMPact® Patient Metric, Kantar. Available from www.cancermpact.com. Accessed 18 March 2020.


ii NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Uterine Neoplasms V1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed 17 April 2020. SGO Clinical Practice Endometrial Cancer Working Group.


iii Burke WM, Orr J, Leitao M, et al. Endometrial Cancer: a review and current management strategies: part II. Gynecol Oncol. 2014;134(2):393-402.


iv Brooks RA, Flemming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258-279.


v Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766-1772.


vi Le DT, Durham JN Smith KN, et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.


vii Lorenzi M, Amonkar M, Zhang J, et al.  Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumor: a structured literature review. Journal of Oncology. 2020; Article ID 18079.


viii Backes FJ, Haag J, Cosgrove CS, et al. Mismatch repair deficiency identifies patients with high-intermediate risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: a prognostic biomarker. Cancer. 2019;125(3):398-405.


ix Endometrial Cancer Treatment (PDQ®) – Health Professional Version. National Cancer Institute. https://www.cancer.gov/types/uterine/hp/endometrial-treatment-pdq. Accessed May 2020.


x Cancer Facts & Figures 2021. American Cancer Society.  Accessed 30 March 2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf.


xi Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101(3):520-529.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-grants-accelerated-approval-for-gsks-jemperli-dostarlimab-gxly-for-women-with-recurrent-or-advanced-dmmr-endometrial-cancer-301275456.html

SOURCE GlaxoSmithKline plc

Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress

Top Experts Convene to Discuss the Syndemic of COVID-19 & Cardiometabolic Disease

Boca Raton, FL, April 22, 2021 (GLOBE NEWSWIRE) — Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress

Top Experts Convene to Discuss the Syndemic of COVID-19 & Cardiometabolic Disease

The 2021 CMHC Spring concluded on Sunday, April 18; delivering two and a half days of critically curated content and expert perspectives on the management of cardiometabolic disease and cardiometabolic risk, as well as special sessions on the impact of COVID-19 on cardiometabolic disease, including a keynote address and panel discussions on the disproportionate burden & disparities with COVID-19.  The “syndemic” of the COVID-19 pandemic along with the rising rates of obesity, diabetes, cardiovascular disease, and other cardiometabolic health conditions, has posed significant challenges to the healthcare community and will continue to do so in the near future; such topics were vastly covered during the meeting. 

The event was delivered entirely online to practitioners across the nation, and through an innovative and user-friendly virtual platform participants were able to interact with faculty members, participate in audience polls, and more, all from the setting of their own choosing.  Chaired by an esteemed panel of faculty members Robert H. Eckel, MD; Christie M. Ballantyne, MD; George L. Bakris, MD; Anne L. Peters, MD; Deepak L. Bhatt, MD, MPH; Keith C. Ferdinand, MD; Clyde W. Yancy, MD, MSc, MACP; and Pamela B. Morris, MD, the conference provided actionable insights on late-breaking research, advanced clinical approaches to cardiometabolic challenges, and practical strategies to improve patient outcomes. 

Keynote: Call to Action: Addressing the Disproportionate Burden & Disparities with COVID-19

The COVID-19 pandemic has resulted in significant morbidity and mortality across the world and is showing no signs of slowing down. As we have started to better understand the impacts of COVID-19, at the same time, there is much uncertainty, limited evidence, and conflicting reports on managing patients with chronic conditions in this new area, which can all impact delivery of care and overall patient outcomes. By now, it is established that the burden of cardiometabolic risk, including CVD, diabetes, atherosclerosis, hypertension, obesity, and more, is higher in certain racial and ethnic minorities, including African Americans, LatinX, and Native Americans. As such, it is by no means a coincidence that the burden of COVID-19 morbidity and mortality is disproportionate towards these communities, stemming not only from a higher prevalence of the comorbidities but also from socio-economic factors. As a focus on these disparities and undue burden, during the meeting’s keynote address, CMHC’s Senior Planning Committee member Keith C. Ferdinand, MD, discussed rationale for these disparities, including genetic, socio-economic, and cultural factors.  Dr. Ferdinand mentioned that “the pandemic is new, but these health inequities are not.” As vaccines for COVID-19 are now available, efforts must be made to not only ensure access to them in racial and ethnic minority populations but also how to effectively combat vaccine hesitancy that is high in these populations, in part due to historical mistrust and previous bias towards healthcare systems. Dr. Ferdinand also highlighted practical steps, tips, and strategies that clinicians can implement in their practices to close these gaps and educate their patients about the benefits of COVID-19 vaccines that will ultimately improve COVID-19 outcomes in underserved populations. The address was followed with a stimulating panel discussion between several key stakeholders and experts, including Kevin M. Alexander, MD, Yvonne Commodore-Mensah, Ph.D., Takeisha C. Davis, MD, MPH, Alanna A. Morris MD, and Pam R. Taub, MD, who discussed systemic racism in healthcare and how to address these disparities. They also highlighted the crucial role of patient education and provided numerous tips to address implicit bias and expand the cultural competency of clinicians.

KIDNEY DISEASE/HEART FAILURE/HYPERTENSION

This session was chaired by George L. Bakris MD and included a special symposium on “New Frontiers in Heart Failure Management,” in whichAlanna A. Morris MD, emphasized that “there is a need of a new way to define heart failure.” She also accentuated that “we are now recognizing a new, universal definition of heart failure” while discussing a new expert statement in the definition and classification of heart failure.  Following this talk, Stephen D. Wiviott, MD, provided crucial clinical pearls regarding the application of SGLT2i in the prevention and treatment of heart failure. He stressed that “now compelling evidence supports that SGLT2i reduces the risk of hospitalization for heart failure as well as robustly decrease the risk of progression of kidney disease.” He also reminded us that “society guidelines are catching up with these fast-moving data.” Following this talk, Ileana L. Piña, MD, discussed the new and emerging targets in heart failure, including new vasodilators, synthetic natriuretic peptides, binders of acting -myosin, etc., and summarized the data from clinical trials, assessing these novel agents to manage heart failure. Due to rapid advancements in the therapeutic landscape of heart failure, the guidelines need to be swiftly updated. The next speaker, Clyde W. Yancy, MD, perfectly summarized the previous talks and outlined potential crucial updates in the guidelines due to advancements in recent heart failure treatments. He successfully painted a clear picture of how HF guidelines might look like in 2021 and beyond, including a stronger emphasis on HF prevention, incorporation of SGLT2is and other newer therapies, as well as more inclusive considerations about health equity in the care of HF patients. This symposium concluded with a fascinating case presentation by Sarah Chuzi, MD, with an interactive panel discussion. After the break, Joseph A. Vassalotti, MD, brought the attendees’ focus from heart failure to kidney diseases and described various strategies that clinicians can employ for evaluating the risk of chronic kidney disease (CKD) progression. This was followed by Aldo J. Peixoto, MD, who shared insights and discussed recent updates in the prevention and treatment of CKD, including the updates in the KDIGO guidelines and the data with SGLT-2is, GLP-1 RAs, and novel non-steroidal MRAs for CKD. William F. Young, Jr., MD, MSc, then discussed the causes and treatment of primary aldosteronism and how it can be easily missed during diagnosis. These sessions were also followed by a panel discussion of different challenging cases of patients with CKD and various comorbidities.

DIABETES MANAGEMENT

As glycemic control remains elusive for a significant proportion of diabetes patients, the management of glycemic control in patients with diabetes and cardiovascular disease risk seems to have taken a backseat. Additionally, new agents and devices are in the development or approval phase that may help clinicians address ongoing needs in diabetes management. To bring this knowledge from trials to our clinicians, this diabetes management session, moderated by CMHC Chair Anne L. Peters, MD, aimed to seek, address and provide a solution to pertinent topics such as effective management of glycemia in patients with cardiovascular diseases byVanita Aroda, MD, benefits of using CGMs in patients with type 2 diabetes and pre-diabetes and co-relation of “time in range” data with complications in diabetes by Viral Shah, MD and Nicholas B. Argento, MD, FACE, respectively. Benefits and how an increased usage of insulin pumps and inpatient use of CGM can optimize treatment and improve the outcomes in diabetes patients was advocated by Grazia Aleppo, MD, FACE, FACP, and Joseph A. Aloi, MD with the help of a solid trail of evidence laid by latest clinical trials and FDA approvals of many devices. To round it out, Jane Reusch, MD, explained how exercise is still an effective medicine for treating type 2 diabetes. The session ended with an extensive discussion between all the faculty that included intriguing case presentations.

OBESITY AND LIFESTYLE MEDICINE

This session chaired by Robert H. Eckel, MD took an in-depth look at obesity prevention and management by discussing comprehensive approaches, including nutritional and lifestyle modifications and recent trends in obesity treatment. Louis J. Aronne, MD kick-started the session by discussing significant ongoing developments in obesity, such as obesity pharmacotherapy, telehealth, and flexibility in dietary interventions. This talk was followed by Donna H. Ryan, MD, who provided many valuable and practical tips to help clinicians help their patients succeed in their weight loss journeys. Dr. Ryan mentioned that “like a thumbprint, every patient’s weight journey is unique.” This was followed by a panel discussion, with case presentations from each faculty and active audience participation.

In the second half of this session, expert faculty supported the benefits of dietary intervention and how it improves patients’ cardiometabolic health backed by recent results from various clinical trials and studies. To that end, Kim A. Williams, Sr., MD, Penny M. Kris-Etherton, Ph.D., and Sarah Hallberg, DO reviewed the benefits of a vegetarian diet, low carbohydrate diets, and dietary recommendations from recent guidelines on cardiometabolic health. This was followed by a stimulating panel discussion with diverse cases and perspectives.

DYSLIPIDEMIA/ATHEROSCLEROSIS/THROMBOSIS

This session focused on discussing CVD prevention in the cardiometabolic patient by exploring topics including CV risk assessment and the evolution of lipid therapy and lipid targets in light of the evolving evidence and guidance. Chaired by Christie M. Ballantyne, MD, this session also addressed the pertinent need of individualizing lipid therapy. Matthew J. Budoff, MD, discussed the role of biomarkers, imaging, and genetics in risk prediction, and Brendan M. Everett, MD updated clinicians on atherosclerotic cardiovascular diseases and how inflammation is a consistent predictor of cardiovascular risk, followed by Pamela B. Morris, MD, who discussed the recent data from clinical trials and stressed that “lower LDL-C is better and lowest is best.” Elaine M. Hylek, MD steered us to the world of atrial fibrillation and discussed stroke prevention strategies in cardiometabolic patients whereas, Deepak L. Bhatt, MD discussed updates in antiplatelet and antithrombotic therapy in cardiometabolic patients. This session also ended with a panel discussion that included an exciting case presentation from all the above faculty, including Margo B. Minissian, Ph.D.

Furthermore, there were two CME symposia: “Antithrombotic Therapy for Symptomatic PAD: Interpreting the Evidence and Recent Advances” and “Lipid Management in Very High-Risk Patients Post-MI: Applying Real-World Evidence to Improve Outcomes.” In the first symposium, Deepak L. Bhatt, MD,Marc P. Bonaca, MD, MPH, and Manesh R. Patel, MD, explored the role of antithrombotic agents in PAD, as outlined by recent clinical trials, as well as illustrated these advancements with the help of a complex patient case that considered how to administer antithrombotic and antiplatelet therapy in PAD patients. In the second symposium, Pam R. Taub, MD, Nihar R. Desai, MD, and Michael D. Shapiro, DO, explored the recommendations suggested by current guidelines for lipid therapy specifically after the incident of myocardial infarction and discussed not only recent clinical trial data but also real-world evidence.  This session ended with a panel discussion of a challenging case.

Cardiometabolic Risk and COVID-19: Implications and Practice Considerations

The special Summit that marked the last day of CMHC Spring explored the connections between cardiometabolic risk and COVID-19, including the increased risk of patients with cardiometabolic disease for severe COVID-19 well as how the pandemic has impacted and continues to impact the management of existing cardiometabolic conditions. CMHC chair, Robert H. Eckel MD, chaired this session, and experts such as Chip Lavie, MD, Clyde W. Yancy, MD, and Jay H. Shubrook DO FACOFP, FAAFP from the cardiometabolic world discussed the brunt of COVID-19 on patients who are obese, have cardiometabolic comorbidities, and how there is a bidirectional relationship between diabetes, obesity, CVD, and COVID 19. They also discussed a need for a solid “game plan” to fight this disease and the resumption of various activities post-COVID-19. This activity concluded with an eventful discussion on challenging case presentation of treatment of an athlete who suffered from COVID-19, as well as a patient with diabetes who contracted COVID-19.

The pandemic has significantly affected the delivery of patient care, especially for patients with cardiometabolic diseases. Faced with these new challenges, clinicians need to find ways such as telemedicine to continue to monitor and treat their patients and deliver multidisciplinary care. Recognizing its importance, the last leg of this session was dedicated to discussing the role and evolution of telemedicine, specifically during the COVID-19 pandemic. On that account, experts Bartolome Burguera, MD, Ph.D., Daichi Shimbo, MD, Anne L. Peters, MD, and Ahmed M. Soliman, MD, educated clinicians about the emerging role of telemedicine and gave them practical steps on how to implement these to practice to ensure the continuum of care for obesity, hypertension, and glucose monitoring with an essential lesson on optimizing reimbursement in telemedicine.

This session also ended with an extensive and interactive panel discussion and provided us insights into this area of need during this syndemic.

Conclusion

Developed and led by the foremost clinicians, researchers, and industry thought leaders, the 2021 CMHC Spring delivered top-tier clinical perspectives from a myriad of specialties. Designed in direct response to the real-world clinical needs of active cardiometabolic practitioners and patients of all backgrounds, this cutting-edge event disseminated the latest science and clinically equitable strategies in cardiometabolic medicine available.  If you are interested in learning more about these challenges, we recommend that you attend the upcoming 16th CMHC Annual meeting, which will be offered both in-person and live streamed from October 14-17, 2021.  Additionally, do not lose the opportunity to learn more about sleep disorders and cardiometabolic health during a unique 1-day masterclass titled “The Intersection of Cardiometabolic Health and Sleep Disorders”, taking place live online on May 22, 2021. CMHC Spring 2021 was recorded and will be available for Accredited Continuing Education credits for one year.



Amanda Jamrogiewicz, CHCP
Cardiometabolic Health Congress
561-997-0112
[email protected]